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Lymphoma is a broad term for a diverse group of neoplastic diseases of 
lymphocytes. In human oncology precise lymphoma subclassification, often 
based on immunohistochemistry (IHC) and molecular genetic abnormalities, 
allows accurate prognostication and treatment. Currently in canine oncology 
such precise subclassification is not possible. As a result, the prognosis and 
treatment of canine lymphoma is less tailored to a patient’s specific disease. 
This study has two parts, each aimed at improving our ability to subclassify 
canine lymphomas. The first part involved investigating novel IHC stains in a 
group of canine lymphoma samples to identify their staining characteristics, 
with a focus on canine T-cell lymphomas (cTCL). The second investigated the 
prevalence and characteristics of TRAF3 mutations in a group of canine B-cell 
lymphomas (cBCL) and assessed cTCL and non-lymphoma samples to see if 
TRAF3 mutations are specific to cBCL. 
For IHC investigation, 46 cTCL and 13 cBCL samples were assessed using c-Kit, 
CD30 and clusterin. Five, three and 11 cases were positive for c-Kit, CD30 and 
clusterin respectively. Three cases of cBCL were positive for clusterin and 
none were positive for either CD30 or c-Kit. 
For TRAF3 investigation, 49 dogs were included (n= 24 cBCL; n= 25 non-cBCL). 
Eleven dogs had matched non-tumour DNA assessed to determine if mutations 
were germline or somatic. All dogs had TRAF3 assessed by Sanger sequencing. 
The prevalence of deleterious TRAF3 mutations in cBCL was 36%. A 
deleterious TRAF3 mutation was suspected to be germline in 1/5 cases with 
matched non-tumour DNA available for comparison. Deleterious mutations 
were not found in specimens from the non-cBCL group. Several synonymous 
variants were identified in cBCL and non-cBCL samples, which likely represent 
polymorphisms. These results indicate TRAF3 mutations are common in cBC 
and may be important in the pathogenesis of cBCL.  
These investigations have used novel IHC markers and TRAF3 analysis to 
characterise a broad group of canine lymphomas. Further investigation is 
needed to investigate if these characterisations are useful in prognosticating 
or directing treatment in dogs with lymphoma.   
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Lymphoma is a broad term for a diverse group of neoplastic diseases of 
lymphocytes. Lymphoma is the most common haematopoietic malignancy in 
dogs and makes up 7-24% of all canine cancers (Vail et al., 2019).  
 
Currently canine lymphomas are largely subclassified on an ad hoc basis, 
directed by owner factors (financial resources, willingness to treat etc) and 
availability of diagnostic tests and veterinary oncologic knowledge. Commonly 
canine lymphomas are subclassified primarily on anatomic location (eg 
multicentric nodal, alimentary, epitheliotropic etc), grade/cell size based on 
cytologic/histopathologic review of cell morphology and mitotic index, and 
basic immunophenotyping. No genetic profiling is used clinically in veterinary 
lymphoma diagnosis and management apart from PCR for antigen receptor 
rearrangement (PARR) to confirm clonality. 
 
Immunophenotyping used in veterinary lymphoma management is almost 
exclusively limited to determining whether the neoplastic population is of B-
cell or T-cell origin. This can be performed in several ways, including 
immunohistochemistry (IHC), immunocytochemistry, and flow cytometry. PARR 
results can also estimate immunophenotype, however this is considered less 
reliable due to reported lineage infidelity in PARR results (Burnett et al., 2003). 
 
Precise lymphoma subclassification is essential to accurately prognosticate and 
direct therapy. There are several examples in veterinary lymphoma treatment 
where subclassification alters treatment and prognosis. Examples include: 
possibly improved outcomes in high-grade T-cell lymphoma (TCL) when treated 
with alkylator-rich multiagent chemotherapy, as opposed to standard 
doxorubicin-based multiagent protocols used for B-cell lymphoma (BCL) (Brown 
et al., 2018); and improved prognosis with T-zone lymphoma (TZL) as diagnosed 




As outlined below, human lymphoma subclassification is far more advanced and 
over 80 lymphoma subtypes are recognised (Swerdlow et al., 2008). In canine 
oncology such precise subclassification is not yet possible, in part due to the 
absence of validated immunohistochemical and genetic markers, and due to 
the difficulty in performing large scale clinical trials to assess potential 
subclassification markers for prognostic or therapeutic significance. The driving 
aim behind this thesis is to try and identify new ways to subclassify canine 
lymphomas which can then be investigated for prognostic and therapeutic 
significance. 
 
1.2 Classification of lymphoma 
 
There have been several histological systems of classification for lymphoma in 
humans. The 2008 WHO classification of tumours of haematopoietic and 
lymphoid tissues (Swerdlow et al., 2008), revised in 2016 (Swerdlow et al., 
2016), is the most common classification system currently used. This has been 
found to be a practical classification system for canine lymphomas (Valli et al., 
2011) although an earlier study found that the previously used Kiel and Working 
Formulation lymphoma classification systems could also be applied to canine 
lymphoma (Fournel-Fleury et al., 1997). The most commonly diagnosed 
histological subtype of lymphoma in humans and dogs is diffuse large B-cell 
lymphoma (DLBCL) which is histologically similar to DLBCL in humans (Ponce et 
al., 2010, Seelig et al., 2016). Table 1-1 outlines the common canine lymphoma 





Table 1-1. Common canine lymphoma subtypes and their proportion of all 
lymphoma cases in dogs and humans. 
Lymphoma subtype Proportion of 
canine cases 
(Vail et al., 
2019, Ponce 















22-52% 31% Most common subtype in 
both species. Human 
DLBCL further 
subdivided into ABC and 





2-15% 4% Heterogeneous group of 
diseases which cannot 






2-12% 4% Mycosis fungoides is the 
most common subtype 













DLBCL: diffuse large B-cell lymphoma; PTCL-NOS: peripheral T-cell lymphoma, 
not otherwise specified; LBL: lymphoblastic (T-cell) lymphoma; TZL: T-zone 




Critical to the classification of lymphoma in humans is the use of IHC and 
molecular genetic tools to make a diagnosis of a specific lymphoma subtype. 
 
IHC uses antibodies to demonstrate the presence of specific antigens within 
tissue sections (Ramos-Vara, 2005). Briefly, IHC involves the preparation of 
histology slides to expose specific tissue antigens (“antigen retrieval”). 
Antibodies are then applied to the slide for the purpose of binding specifically 
to the desired antigen. A second antibody is then applied which binds to the 
first antibody. This second antibody is conjugated to an enzyme (most 
commonly peroxidase) which then catalyses a colour-producing reaction which 




Often canine nodal and extranodal lymphoma is diagnosed using only samples 
that can be obtained using minimally invasive methods such as fine needle 
aspirates in order to reduce the financial cost to the owner and perceived 
invasiveness of general anaesthesia and biopsies on the dog. Fine needle 
aspirates produce cytological samples which can be assessed to determine cell 
size and morphology, however cannot provide information regarding the tissue 
architecture. Fine needle aspirate material can also be placed in a suspension 
and assessed using flow cytometry. Flow cytometry is able to sort cells in a 
suspension based on numerous criteria including size, granularity and 
fluorescent markers (Wilkerson, 2012). By attaching fluorescent markers to 
antibodies, flow cytometry can provide reliable immunophenotypic information 
(Wilkerson, 2012). Flow cytometry is able to differentiate canine lymphomas 
into distinct categories which often correlate with histopathologic and 
immunohistochemical features. In particular, flow cytometry can accurately 
predict a histologic/immunohistochemical diagnosis of T-zone lymphoma on the 
basis of T-cell marker positivity and CD45 negativity (Seelig et al., 2014, 
Comazzi and Riondato, 2021). Other examples, include flow cytometric 
immunophenotype CD45+CD3+CD8+CD4-MHC II- correlating with cutaneous T-
cell lymphoma, and CD4+ lymphomas having a consistent histologic and gene 
expression profiles (Harris et al., 2019, Comazzi and Riondato, 2021). Flow 
cytometry is also prognostic in canine lymphoma (Avery et al., 2014). Flow 
cytometry is a non-invasive method that can correlate with histopathologic and 
immunohistochemical parameters, however histopathology and 
immunohistochemistry remain vital for definitive diagnosis, as there can be 
significant overlap between different canine WHO lymphoma subtypes when 





There are numerous molecular genetic tools available for use in investigating 
and subclassifying lymphoma. At their core these tools identify alterations in 
the genetic makeup of tissues, including chromosomal aberrations (eg copy 
number aberrations, fusions), mutations, and changes in gene expression. 
Polymerase chain reaction (PCR) based techniques allow the investigation of 
specific known DNA sequences to accurately interrogate the DNA sequence for 
abnormalities. Next generation sequencing (NGS), also known as massively 
parallel sequencing, is a more recent technology. NGS allows the entire 
genome, exome, or transcriptome to be sequenced and compared against a 
refence sequence to identify all mutations and abnormalities present. NGS such 
as RNA-Seq also allows for the quantification of gene expression and thereby 
allows the gene expression profile of different tumours to be measured. 
Identification of genes and metabolic pathways that are upregulated or 
downregulated can give insights into tumourigenesis and potential therapeutic 




In humans accurate diagnosis of lymphoma into specific subclassifications 
requires the use of these tools. For example, the diagnosis of anaplastic large 
cell lymphoma (ALCL), a T-cell lymphoma, requires CD30 IHC positivity for 
diagnosis, and it is then further subclassified into anaplastic lymphoma kinase 
(ALK) positive ALCL or ALK negative ALCL on the basis of ALK IHC (Swerdlow et 
al., 2008), and human DLBCL is subclassified into germinal centre B-cell (GCB) 
subtype and activated B-cell (ABC) subtype on the basis of gene expression 
profiling (Swerdlow et al., 2008). Subsequent to the discovery of these DLBCL 
subtypes based on gene expression profiling, immunohistochemical panels (such 
as CD10, BCL6 and IRF4/MUM1) have been devised to more practically 
distinguish GCB from non-GCB DLBCL subtypes (Hans et al., 2004). The use of 
similar tools in canine lymphoma classification is less advanced; however it is 
progressing. In a seminal paper applying the WHO classification to canine 
lymphomas (Valli et al., 2011), the only diagnostic testing performed, beyond 
morphological assessment, was IHC immunophenotyping with the B-cell marker 
CD79a and T-cell marker CD3. Until further IHC markers and molecular profiling 
techniques are validated in veterinary medicine, precise lymphoma 
subclassification will remain beyond our grasp. Precise subclassification is 
critical for prognostication and for designing studies to determine optimal 
therapeutic strategies.  
 
1.3 Immunohistochemical markers in lymphoma 
IHC is integral in subclassifying lymphomas by differentiating morphologically 
identical populations of neoplastic cells into specific subgroups. No 
immunostain is 100% specific, and therefore panels of stains should always be 




Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a diagnosis 
assigned to a nodal or extra nodal mature T-cell lymphoma that cannot be 
assigned to any of the recognised specific T-cell lymphoma entities in the 
current WHO classification scheme (Swerdlow et al., 2008). In dogs PTCL-NOS 
is the second most common lymphoma subtype, making up about 15% of all 
lymphoma cases (Valli et al., 2013, Valli et al., 2011, Seelig et al., 2016). In 
humans, PTCL-NOS make up only 1% of lymphoma cases, and only 4% of non-
Hodgkin’s lymphomas (Jha et al., 2017, Seelig et al., 2016). This difference is 
no doubt in part due to the ability to differentiate human PTCL into numerous 
specific subtypes. These include angioimmunoblastic T-cell lymphoma, nodal 
PTCL with T follicular helper phenotype, adult T-cell leukaemia/lymphoma, 
ALK positive ALCL, and ALK negative ALCL among others (Swerdlow et al., 
2008). These subclassifications are largely based on immunophenotyping via 
flow cytometry and IHC. 
 
As previously mentioned, CD30 and ALK IHC are routinely evaluated in human 
PTCL, as CD30 positive cases can be classified as ALCL. ALK is prognostic in 
ALCL, with ALK positive cases having a significantly improved prognosis 
(Gascoyne et al., 1999, Swerdlow et al., 2008). Another routine distinction is 
whether the neoplastic cells are of follicular T-helper cell (Tfh) phenotype. Tfh 
phenotype is assigned if the cells are positive for at least two of the following 
Tfh markers: CD10, BCL6, PD1, CXCL13, CXCR5, ICOS, or SAP. 
 
These markers have not been assessed in canine lymphoma. Particularly, 
subclassification of canine T-cell lymphomas remains difficult. A lack of 
methods to subclassify TCL results in most canine TCL being diagnosed as PTCL-
NOS. From studies assessing canine TCL, inevitably a wide range of outcomes is 
seen (Moore, 2016, Goodman et al., 2016, Brown et al., 2018). This suggests 
that, like human TCL, canine TCL comprises a variety of specific subtypes, and 
if we were able to identify these subtypes we may be able to better 




With this goal in mind, we selected the following markers as being potentially 
useful for the subclassification of canine T-cell lymphomas: CXCR5, CD30, ALK, 
clusterin, c-Kit and PD-1. See Table 1-2 for a summary of an overview of these 





Table 1-2. Selected IHC markers used in human and canine lymphoma. 
Marker Role in human lymphoma Use in canine disease 
CXCR5 • Identify Tfh • No role 
CD30 • Required for diagnosis of 
ALCL 
• Reed-Sternberg cells 
positive 
• Marker of ALCL 
• Marker of mast cells 
ALK • Prognostic in ALCL • No role 
Clusterin • Not routinely used, 
however is a possible 
marker for ALCL 
• No role  
 
c-Kit • No defined role • No role in lymphoma 
• Diagnostic and prognostic 
in mast cell tumours 
PD-1 • Identify Tfh • No role 





CXCR5 is a chemokine, which are small peptides that direct the migration of 
leucocytes. It is a marker of Tfh, and is used in the subclassification of PTCLs 
(Swerdlow et al., 2008). It was first identified in Burkitt’s lymphoma and is also 
termed Burkitt’s lymphoma receptor 1. 
 
CXCR5 (as well as CCR7) acts as a homeostatic chemokine receptor and is a 
major regulator of the adaptive immune response (Murphy, 2019). CXCR5 plays 
a key role in lymphocyte migration through the lymph node microenvironment. 
It is expressed by mature recirculating B-cells (however not plasma cells) 
(Hargreaves et al., 2001), some dendritic cells, as well as a subset of CD8 
positive and CD4 positive T-cells, most notably Tfh (Burkle et al., 2007). Tfh 
are able to migrate following activation from the T-zone to the follicles where 
they provide help for B-cell maturation and antibody production. The ligand for 
CXCR5, CXCL13, is a homeostatic chemokine that is constitutively secreted by 
stromal cells in B-cell areas of secondary lymphoid tissues (follicles) where B-
cells encounter antigen and differentiate. CXCR5 activation results in the 
recruitment of naïve B-cells to follicles (Burkle et al., 2007). 
 
Tfh malignancies, such as angioimmunoblastic T-cell lymphoma and ~20% of 
PTCL-NOS show high levels of CXCR5 expression (Ahearne et al., 2014). Some 
of these lymphomas morphologically appear similar to ALCL, however their 
derivation from Tfh suggest a separate pathogenesis. 
 
CXCR5 is also widely expressed in B-cell neoplasms including B-cell chronic 
lymphocytic leukaemia, hairy cell lymphoma, mantle cell lymphoma, mucosal-
associated lymphoid tissue lymphomas, follicular lymphoma, and DLBCL (Pals 
et al., 2007).  
 





CD30 is a type one transmembrane receptor and member of the tumour necrosis 
factor receptor superfamily (Pierce and Mehta, 2017, Sotomayor et al., 2014), 
which is formed of intracellular, trans-membrane and extracellular domains 
(van der Weyden et al., 2017). During early gestation, CD30 expression is found 
within a variety of organ systems including the gastrointestinal tract, post 
pharyngeal foregut, urinary, musculoskeletal, reproductive, endocrine, 
nervous, haematolymphoid, and integumentary systems (Sotomayor et al., 
2014). After three months of gestation CD30 expression becomes much more 
restricted, primarily to the haematolymphoid system (Sotomayor et al., 2014).  
 
CD30 is involved in T-cell immune response and regulation. It plays a role in T-
cell proliferation in response to T-cell receptor stimulation, acting as a 
costimulator in secondary T-cell response, as well as stimulating production of 
cytokines (IL-2, TNF, IFN-y) by T-cells (Horie and Watanabe, 1998, Pierce and 
Mehta, 2017). Studies in knock-out mice suggest CD30 has a role in immune-
surveillance and cross-talk between B- and T-cells (van der Weyden et al., 
2017).  
 
CD30 transduces signals via the recruitment of TNF receptor-associated factor 
(TRAF) and TRAF-binding proteins. Binding of TRAF1, 2 and 5 has been 
documented, which stimulate the nuclear factor kappa B, mitogen-activated 
protein kinase and extracellular signal-regulated kinase pathways. Activation 
of these pathways results in anti-apoptotic and pro-survival mechanisms within 





According to the WHO classification system for lymphoma (Sabattini et al., 
2010), CD30 positivity is required for a diagnosis of anaplastic large cell 
lymphoma (ALCL). Nearly all cases of Hodgkin’s lymphoma (HL) are also CD30 
positive. Various other forms of lymphoma have shown variable CD30-positivity 
(Sabattini et al., 2010), including enteropathy-associated T-cell lymphoma I 
(EATL-I), although not EATL-II, as well as Epstein Barr virus positive DLBCL, 
PTCL-NOS, and mycosis fungoides (Pierce and Mehta, 2017). 
 
ALCL can be classified according to the WHO guidelines as primary cutaneous 
or systemic (Swerdlow et al., 2016). The systemic form is most common 
however up to 60% have extranodal involvement. The systemic form can be 
further subdivided into ALK positive and negative. ALCL has a classic 
morphology showing atypical lymphoid cells with pleomorphic or horseshoe 
nuclei and abundant cytoplasm(2016). 
 
CD30 expression has been assessed as a prognostic indicator in DLBCL with 
conflicting results (Hao et al., 2015, Hu et al., 2013), however it is correlated 
with other poor prognostic indicators such as bone marrow involvement, non-
germinal centre B-cell like DLBCL, and BCL-2 and Ki-67 overexpression (Hao et 
al., 2015). It is thought that soluble serum CD30 levels may correlate with 
progression of disease and poorer prognosis in CD30 positive lymphomas 
(Sotomayor et al., 2014). 
 
CD30 staining is obligatory in cases of human ALCL (Pierce and Mehta, 2017). In 
these cases the neoplastic cells display a membranous/golgi-associated staining 
pattern. In a case study using CD30 IHC in a dog, the neoplastic lymphocyte 
population also showed membranous staining (Pittaway et al., 2018) while in a 
case series of 13 dogs with intestinal ALCL, 50-100% of neoplastic cells showed 




Several studies have reported using CD30 IHC in canine patients with neoplastic 
and non-neoplastic diseases (Park et al., 2007, Pittaway et al., 2018, Hohsteter 
et al., 2014, Bauer et al., 2017, Stranahan et al., 2019). CD30 IHC positivity was 
identified in a case report of a dog with pulmonary lymphomatoid 
granulomatosis (Park et al., 2007). Since in humans CD30 can be used to 
differentiate testicular embryonal carcinomas (Emerson and Ulbright, 2005) a 
2009 study assessed CD30 positivity in canine seminomas and Sertoli cell 
tumours, however all 35 samples (20 seminomas, 15 Sertoli cell tumors) were 
negative (Yu et al., 2009). A later study assessed 105 testicular tumours and 
found 7% were CD30 positive (Hohsteter et al., 2014). Of those cases that were 
CD30 positive, only 5-10% of cells showed positivity (Hohsteter et al., 2014). 
 
A study assessing atopic dermatitis in dogs successfully identified CD30 positive 
lymphocytes in circulation using flow cytometry (Olivry et al., 2011). Bauer et 
al (Bauer et al., 2017) assessed CD30 expression in canine mast cell tumours. 
As part of this study CD30 IHC was assessed in 31 canine mast cell tumour 
samples and in all cases the neoplastic cells showed diffuse positive staining.  
 
Two studies exist using CD30 in canine lymphoma. The first was a case study 
which used CD30 to diagnose ALCL in a dog with CD3 and CD79a negative 
lymphoma (Pittaway et al., 2018). The second used CD30 to diagnose intestinal 
ALCL in a case series of 13 dogs (Stranahan et al., 2019). This study was the 
first to describe intestinal ALCL in dogs.  
Valli et al described a cutaneous form of ALCL in cats associated with injection 
sites, and also a nodal form which typically also involves generalised skin 
disease and dependent oedema, however these reports did not include CD30 
immunostaining. A recent study assessed CD30 IHC in a variety of feline 
lymphomas and found that 13% of T-cell lymphomas, 14% of B-cell lymphomas, 




CD30 is attractive as a therapeutic target due to the limited expression of CD30 
by normal cells. Multiple methods have been trialled in human oncology to 
target CD30, including monoclonal antibodies and antibody-drug conjugates 
(Pierce and Mehta, 2017).  
 
Brentuximab vedotin is an antibody-drug conjugate which targets the CD30 
membrane receptor. It consists of a human monoclonal anti-CD30 antibody 
which is covalently linked to the microtubule disrupting agent monomethyl 
auristatin E (Scott, 2017). Binding of brentuximab vedotin to CD30 positive 
tumour cells initiates a cascade that ultimately results in apoptosis. 
Brentuximab vedotin currently has FDA approval for the treatment of relapsed 
HL, ALCL, primary cutaneous ALCL and CD30 positive mycosis fungoides, as well 
as first line treatment of advanced stage HL. 
 
An in vitro study found that brentuximab vedotin induced growth inhibition and 
apoptosis in canine mast cell tumour cell lines, and that there was synergistic 
activity when brentuximab vedotin was combined with the tyrosine kinase 
inhibitor masitinib (Bauer et al., 2017).  
 
In humans, it is unknown whether CD30 expression levels, quantified by staining 
intensity and distribution on IHC, relate to response to anti-CD30 therapies (van 
der Weyden et al., 2017). 
 
No studies exist examining CD30 in a variety of canine lymphomas or as a 





Anaplastic lymphoma kinase (ALK), also known as CD246, is a receptor tyrosine 
kinase (RTK) of the insulin receptor superfamily. It plays roles in normal 
development and in oncogenesis. ALK has a similar structure to other RTKs, 
with an extracellular ligand-binding region, transmembrane region, and 
cytoplasmic tyrosine kinase domain. Within the insulin receptor superfamily, 
ALK is grouped with leucocyte tyrosine kinase due to homology between the 
receptors (Palmer et al., 2009). In humans the ligands known to bind to the ALK 
receptor are pleiotrophin and midkine (Webb et al., 2009). Heparin affinity 
regulatory peptide and heparin-binding neurotrophic factor are also activating 
ligands (Courty et al., 1991) although less is known about these ((Kovesdi et al., 
1990). 
 
In various non-human species, ALK expression is restricted to specific regions 
of the nervous system, eyes, tongue, testis and ovaries (Iwahara et al., 1997) 
(Hurley et al., 2006). ALK levels decrease at the end of gestation and only very 
small quantities are found after birth, with minimum levels reached at three 
weeks of age (Iwahara et al., 1997). Anti-ALK immunocytochemical studies in 
adult humans found only rare staining in neural cells, pericytes and endothelial 
cells of the brain. ALK is predominantly found in the nervous system of 
neonates, which suggests it has a role in the development of this system (Webb 
et al., 2009). However mice engineered without the ALK gene still live a normal 
lifespan with no apparent abnormalities (Webb et al., 2009). 
 
ALK and its ligands have a role in the regulation of cell survival. Pleiotrophin 
and midkine regulate apoptosis, likely at least in part through ALK activity. 
Pleiotrophin, through ALK binding, leads to activation of anti-apoptotic proteins 
(serine/threonine kinases PI3-kinase and protein kinase B). Pleiotrophin plays a 
role in angiogenesis, possibly through ALK activation (Webb et al., 2009). 
Pleiotrophin can also activate ALK without direct pleiotrophin-ALK binding. 
Midkine-mediated ALK activation leads to increased proliferation (via insulin-
like receptor substrate-1 and Shc interaction) by increasing nuclear factor-




Pleiotrophin and midkine have been linked to the proliferation, survival, 
metastasis and angiogenesis of tumours, however it is not clear how much of 
these effects are due to ALK-mediated signal transduction (Webb et al., 2009). 
 
ALK overexpression and gain-of-function mutations have been implicated in 
oncogenic progression (Palmer et al., 2009). ALK overexpression has been 
documented in several human neoplasms, including lymphoma, non-small cell 
lung tumours, thyroid carcinomas, breast cancer, retinoblastoma, 
astrocytomas, Ewing sarcomas and rhabdomyosarcomas (Dirks et al., 2002, 
Kwak et al., 2010). 
 
ALK is involved in oncogenesis as both a full-length ALK receptor and as ALK 
fusion proteins. Full-length ALK receptor involvement in oncogenesis is due to 
ALK over-expression and activating point mutations (Palmer et al., 2009), as 
well as paracrine/autocrine loops involving pleiotrophin and midkine (Webb et 
al., 2009), leading to increased ALK activation. However, ALK fusion proteins 
are the most common ALK abnormalities seen in cancers (Webb et al., 2009). 
ALK fusion proteins result from chromosomal translocations interrupting the 
normal ALK gene (at 2p23). The fusion protein displays self-association which 
mimics normal ligand binding and leads to constitutive activation (Webb et al., 
2009). The most common fusion protein, nucleophosmin-anaplastic lymphoma 
kinase (NPM-ALK), signals via the PLC-y, PI3K, RAK/MAPK and JAK/STAT 
pathways (Palmer et al., 2009). 
 
ALK positivity is also seen in a rare subpopulation of human DLBCL patients and 
is correlated with an aggressive disease and poor response to treatment 
(Reichard et al., 2007). The fusion protein CLTC-ALK is more commonly 
encountered in ALK positive DLBCL cases, as opposed to the NPM-ALK fusion 




ALCL is a T-cell non-Hodgkin’s lymphoma characterised by CD30 expression 
(Palmer et al., 2009). ALK expression is associated with prognosis in human 
ALCL. ALK positive patients have an improved prognosis with significantly higher 
5-year survival rates of 80%, compared to only 48% in ALK negative cases 
(Gascoyne et al., 1999, Swerdlow et al., 2016). Intestinal ALCL is most 
commonly ALK-negative (Savage et al., 2008). 
 
It is not clear to what extent ALK IHC highlights ALK fusion proteins as well as 
full-length ALK receptors (Webb et al., 2009). In ALK positive ALCL, neoplastic 
cells show intense cytoplasmic and nuclear staining. 
 
There have been no studies looking at ALK expression or mutations in canine 
lymphoma. A previous publication (Mariotti et al., 2014) assessed 12 canine 
pulmonary adenocarcinomas and found significantly increased ALK gene 
expression (measured with RT-PCR) in the neoplastic tissue compared to 
adjacent non-neoplastic lung tissue. This study also attempted to characterise 
ALK expression in the adenocarcinomas with IHC, however no samples were 
positively stained. It is unknown whether this was due to lack of ALK expression 
(below detectable level), suboptimal antigen retrieval, or lack of homology 
between the antibody used and canine ALK antigen. 
 
Patients with human non-small cell lung cancer (NSCLC) with ALK fusion 
proteins have been shown to benefit from specific ALK inhibitors (Cabezon-
Gutierrez et al., 2012) such as crizotinib (Kwak et al., 2010). Currently there 
are no commonly used ALK-targeted therapies for human patients with ALK-





Clusterin, also known as glycoprotein III, testosterone-repressed prostate 
message-2, apolipoprotein J and sulphated glycoprotein-2, is a 80kd 
glycoprotein composed of two alpha and beta subunits (Saffer et al., 2002). 
Clusterin is highly conserved across species and is present in varying amounts 
in numerous tissues. It is also frequently identified in body fluids. It is believed 
to play roles in numerous functions including reproduction, lipid transport, 
complement regulation, hormone secretion, and apoptosis (Jones and Jomary, 
2002). 
 
Clusterin is expressed in human lymphoma as well as various carcinomas, 
including mammary, renal, bladder, prostate, and ovary. Most cases of ALCL 
reveal clusterin IHC positivity, leading to some suggesting it as a diagnostic 
marker of ALCL in cases of poorly differentiated round cell tumours 
(Nascimento et al., 2004). 
 
Clusterin has been assessed as a CSF biomarker for chronic spinal disorders in 
dogs (Shafie et al., 2014). This study found that CSF clusterin concentrations 
were increased in cases of degenerative myelitis and intervertebral disc disease 
compared to normal dogs and dogs with meningoencephalitis and idiopathic 
epilepsy. Clusterin IHC in this study revealed neuronal positivity was not 




Clusterin has been evaluated in canine lymphoma in two studies.  Both studies 
evaluated soluble clusterin in serum. The first study assessed the serum 
proteome of 21 dogs with lymphoma compared to healthy dogs. This study 
found measurable quantities of clusterin in 1/21 lymphoma dogs and in none of 
the healthy control dogs (Atherton et al., 2013). The second study specifically 
evaluated soluble serum clusterin levels as a potential biomarker for canine 
lymphoma (McNaught et al., 2020). This study found that serum clusterin levels 
were significantly lower in dogs with multicentric lymphoma compared to 
healthy controls, and no difference was found between dogs before treatment 
and after complete remission was achieved. The authors concluded that 
clusterin had limited potential as a biomarker due to the wide variation in 
clusterin value between individuals.  
 
Clusterin IHC in canine lymphoma has not previously been assessed. 
 
1.3.5 C-Kit 
C-Kit is expressed in myeloid progenitor cells, dendritic cells, mast cells as well 
as pro-B- and T-cells. Normal B- and T-cells lose c-Kit expression during 
differentiation. 
 
C-Kit mutations have been noted in numerous human haematopoietic 
neoplasms, however results in lymphoma have been contradictory (Giantin et 
al., 2013, Rassidakis et al., 2004, Pinto et al., 1994, Brauns et al., 2004, 
Rassidakis et al., 2003) with some studies finding frequent expression of c-Kit 
in specific CD30 positive lymphoma subtypes (HL, ALCL) (Pinto et al., 1994), 
others finding the opposite, with very infrequent expression in CD30 positive 
lymphomas (Rassidakis et al., 2004, Rassidakis et al., 2003), and some finding 
infrequent expression in other specific subtypes (PCTL, mycosis fungoides, 
Sezary syndrome) (Brauns et al., 2004). In a study assessing 56 cases of human 
DLBCL, 37% showed some c-Kit positivity (Vakiani et al., 2005). Another study 
assessing c-Kit IHC in 1166 cases of human lymphoma found only two cases 




A study assessing c-Kit expression in canine lymphoma found that BCLs had low 
expression, as measured by mRNA PCR sequencing and flow cytometry, whereas 
TCLs had variable expression, with c-Kit expression increased in high grade 
more than low grade TCLs (Giantin et al., 2013). This study assessed various 
lymphomas with c-Kit immunocytochemistry (ICC) and found that 6/14 BCLs, 
and 7/11 TCLs were positive. IHC was not assessed (only ICC). A study 
investigating the use of masitinib in the treatment of epitheliotropic T-cell 
lymphoma found no expression of c-Kit when 8 tumours were assessed using 
IHC(Holtermann et al., 2016). A case report of a dog with cutaneous 
epitheliotropic lymphoma identified moderate cytoplasmic to membranous c-
Kit positivity (Shiomitsu et al., 2012). 
 
Overall the utility of c-Kit expression in human and canine lymphomas is 
unknown, however large scale studies of c-Kit expression in canine lymphomas 
are lacking. It remains to be determined if c-Kit IHC can be used for lymphoma 
subtyping and prognostication, or to predict response to therapy (e.g. with c-
Kit inhibitors). 
 
1.3.6 PD-1 and its ligand (PD-L1) 
Programmed death-1 receptor (PD-1) and its ligand, programmed death-ligand-
1 (PD-L1) are immune checkpoint molecules involved in maintaining T-cell 
tolerance to self-antigens. They act to limit autoimmunity by restricting T-cell 
activity in peripheral tissues (Hartley et al., 2018, Gravelle et al., 2017). PD-1 
expression is induced by T-cell activation. Ligation of PD-1 by PD-L1 delivers an 
inhibitory signal which reduces T-cell response. It does this by promoting 
apoptosis in antigen-specific T-cells and reducing apoptosis in regulatory T-cells 
(Tregs) (Hartley et al., 2018). PD-L1 is expressed by immune cells, particularly 





The PD-L1/PD-1 axis is frequently dysregulated in cancer, leading to an 
upregulation of PD-L1 expression on tumour associated macrophages and 
tumour cells. This leads to an increase in PD-1 signalling in T-cells which leads 
to apoptosis, anergy and functional exhaustion of T-cells, aiding in immune 
escape of the tumour (Gravelle et al., 2017). 
 
In human non-Hodgkin’s lymphoma overexpression of PD-L1 by tumour cells and 
PD-1 by tumour infiltrating lymphocytes has been shown (Andorsky et al., 2011, 
Laurent et al., 2015). 
 
A flow cytometric study of canine lymphoma patients found a significant 
number of malignant cells in B-cell lymphoma (20%) showed upregulation of PD-
L1, compared to only 2% of non-neoplastic B-cells. Neoplastic and non-
neoplastic T-cells showed very low PD-L1 expression. In the same study no 
difference was found between malignant and normal B-cells in terms of PD-1 
expression, however no malignant T-cells showed PD-1 expression, compared 
to 50% of normal T-cells (Hartley et al., 2018). Shosu et al used PD-L1 IHC to 
assess various canine tumours and found that PD-L1 was expressed in many 
tumour types, including 15/15 of the lymphoma samples assessed (Shosu et al., 
2016). 
 
A study assessing PD-L1 expression in canine tumour cells macrophages via flow 
cytometry, Western blotting, immunofluorescence imaging and RT-PCR found 
that all tumour cells expressed PD-L1 to various degrees, and concluded that 
PD-L1-mediated T-cell suppression may be an important mechanism of immune 




Anti-PD-1 antibody therapy has shown favourable responses in several human 
cancers (Postow et al., 2015). PD-1 and PD-L1 antibodies had functional effects 
on canine T-cells in a preliminary study (Coy et al., 2017), and a second study 
which assessed the use of a PD-L1 monoclonal antibody as a therapeutic in 
canine oral malignant melanoma and undifferentiated sarcoma found that 1/7 
melanomas and 1/2 sarcomas showed objective responses (Maekawa et al., 
2017). PD-L1 IHC was not used in this study, however it opens the door for the 
use of anti-PD-L1 antibodies as a therapeutic in canine oncology in future. 
 
A recent study (Choi et al., 2020) developed canine anti-PD-1 and anti-PD-L1 
antibodies which were shown to be specific for the intended epitopes. The anti-
PD-1 antibody was successfully used for IHC, and the anti-PD-L1 antibody 
demonstrated functional activity against PD-L1, suggesting it could potentially 
be developed into a therapeutic anti-PD-L1 treatment in future. 
 
No studies have specifically assessed using PD-1 or PD-L1 IHC in a variety of 
canine lymphomas. 
 
1.4 Molecular genetic classification of lymphoma 
Many genes contributing to lymphomagenesis have been identified in human 
oncology, however relatively little is known about the molecular genetic 
abnormalities associated with the development, prognosis and treatment of 
canine lymphoma (Bushell et al., 2015). Recent advances in gene sequencing 
have led to an increase in identification of mutations. The high rate of 
lymphoma in specific breeds, and the propensity for specific breeds to get 
certain types of lymphoma (e.g. T-cell lymphoma in Boxers) indicates an as yet 




Genomic instability is a key feature of all carcinogenesis (Hanahan and 
Weinberg, 2011) and there are numerous types of genetic abnormalities that 
can occur. Broadly, these abnormalities contribute to the formation of cancer 
by the activation of oncogenes or inactivation of tumour suppressor genes. The 
most commonly recognised abnormalities involve genetic mutations which alter 
the genetic sequence. Common types of mutations include point mutations, 
duplications, frameshift mutations, and chromosomal translocations. Sanger 
sequencing is an accurate method of sequencing DNA, although it has several 
limitations. These include the need to know the sequence of the target DNA (in 
order to make primers), only sections of DNA ~500-600 base pairs in length can 
be sequenced, and mutations can only be detected if the prevalence in the cells 
being assessed is over ~10% (poor sensitivity) (de Koning et al., 2015). Common 
mutations identified with Sanger sequencing include point mutations and 
frameshift mutations. Point mutations are the alteration of a single nucleotide. 
These mutations can have several effects including: being silent (no change in 
amino acid), missense (different amino acid), or nonsense (change to a stop 
codon which prematurely terminates the sequence). Frameshift mutations 
insert or delete a number of nucleotides that is not divisible by three, thereby 
altering the reading frame and completely altering the downstream sequence. 
Next generation sequencing (also termed massively parallel sequencing) is a 
powerful tool in assessing the genetic abnormalities in carcinogenesis as it is 
able to overcome many of the limitations of Sanger sequencing. RNA-seq (a 
form of next generation sequencing) sequences the transcribed RNA and so 
permits the identification of any post-transcriptional abnormalities and can 




1.4.1 Molecular profiling in lymphoma 
Human diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous 
group of lymphomas which cannot be further subclassified based on morphology 
alone. However when gene expression profiling is used, DLBCL can be 
subclassified into at least two different groups, including activated B-cell (ABC) 
lymphoma and germinal centre B-cell (GCB) lymphoma. This separation is 
prognostically significant, with GCB DLBCL having a significantly better 
prognosis. GCB DLBCL have a 76% 5-years survival, compared to just 16% with 
ABC DLBCL (Richards et al., 2013).  
 
Constitutive activation of the NFkB pathway has been found in most human 
lymphoid malignancies (Mudaliar et al., 2013). Differential gene expression of 
the NFkB pathway can be prognostic as in the case of human DLBCL, with the 
gene profile of the more aggressive ABC DLBCL showing constitutive NFkB 
activity (Davis et al., 2001).  
 
1.4.2 Molecular profiling in canine lymphoma 
Frantz et al (Frantz et al., 2013) assessed gene expression profiles in six 
common canine lymphoma subtypes (LBT, TZL, PTCL-NOS, Burkitt-like B-cell 
lymphoma, DLBCL, marginal zone lymphoma) and found these subtypes could 
be separated into three distinct groups based on gene expression; high grade 
T-cell lymphoma (LBT, PTCL-NOS), low grade T-cell lymphoma (TZL), and B-cell 
lymphoma (marginal zone lymphoma, DLBCL, Burkitt-like lymphoma). This 
separation was prognostically significant. The study also identified four genes 
(CD28, ABCA5, CCDC3, SMOC2) whose expression could be measured to 
accurately categorise samples into one of the three groups. This study was not 
able to separate the DLBCL group into distinct ABC and GCB groups, however 




Richards et al (Richards et al., 2013) attempted to separate canine B-cell 
lymphoma cases using immunohistochemical algorithms, gene expression 
profiling, and immunoglobulin heavy chain variable region mutational 
assessment. This study found that immunohistochemical algorithms used in 
human oncology to differentiate ABC DLBCL and GCB DLBCL were not useful in 
canine lymphoma. However, gene expression differences were able to separate 
the canine samples into two groups, similar to human GCB and ABC DLBCL. This 
distinction was then used to select a canine-specific set of differentially 
expressed genes. This canine-specific gene expression profile was able to 
identify two groups with significantly distinct progression free survival. 
Furthermore, these canine-specific "ABC/GCB" discriminating genes, while 
different from the human ABC/GCB gene list, are involved in the same pathways 
and processes (e.g. NFkB signalling and B-cell receptor signalling). 
Immunoglobulin heavy chain variable region mutational assessment was also 
able to separate out cases into two distinct groups with significantly different 
survival times. 
 
A study specifically assessing gene expression in canine CD4 positive TCL found 
5011 genes were significantly different in neoplastic CD4 positive T-cells 
compared to control CD4 positive T-cells from healthy dogs (Harris et al., 2019).  
This study assessed six dogs with CD4 positive TCL and compared them to six 
healthy dogs. It found that gene expression was consistent with flow cytometry 
results, with decreased expression of CD5, CD25 and MHC class II correlating 
with negative flow cytometry results for these markers. Parathyroid hormone-
related peptide expression was increased in all cases, regardless of whether the 
patient was clinically hypercalcaemic. Three of the dogs with lymphoma were 
Boxers and it was found that their gene expression was overall not significantly 
different from the dogs of other breeds. However 82 genes were significantly 
different in the Boxers compared to other breeds, with ROS1 being one of the 
most overexpressed genes in the Boxer. SATB1 and PTEN were identified as 
frequently mutated in a previous study (Elvers et al., 2015) however this was 
not seen in this study. Pathway analysis found significant upregulation of PI3K 
and mTOR (both associated with increased cell proliferation) and significant 




Elvers et al compared the somatic mutations of BCL and TCL in three dog breeds 
(Boxer, Golden Retriever, Cocker Spaniel) with different lymphoma 
immunophenotype predispositions (Elvers et al., 2015). This study used 
matched tumour and normal tissue samples to identify somatic mutations and 
compared mutations between BCL predisposed breeds (Cocker Spaniel and 
Golden Retrievers) and TCL predisposed breeds (Golden Retrievers and Boxers). 
On average 18 non-silent somatic mutations were identified in lymphoma cases, 
with TCLs having more mutations than BCLs. Most significantly mutated genes 
were only mutated in either BCL or TCL (not both), with only seven percent of 
mutations being in both groups. The most significantly mutated genes in BCL 
were POT1, FBXW7 and TRAF3. The most significantly mutated genes in TCL 
were SATB1, TBC1D26, PSMA1, COX8A, and PTEN. Mutations in BCLs tended to 
be similar between breeds, however TCLs tended to have very little overlap of 
mutations between breeds. Of the 15 most commonly mutated genes in both 
breeds, only SATB1 was shared. Forty-four percent of boxers had a mutation of 
at least one of the following genes: PI3KCD, PIK3RI, MTOR, and PTEN, but only 
six percent of Golden Retrievers had these mutations. Both breeds had different 




Bushell et al (Bushell et al., 2015) assessed TRAF3 mutations in many cases of 
cBCL. Initial RNA sequencing of 14 dogs identified mutations predicted to alter 
TRAF3 function in 28.6% of dogs. TRAF3 coding exons were sequenced in 63 
confirmed cBCL cases and 30.2% were mutated (a further 4/21 lymphomas of 
unknown phenotype had TRAF3 mutations). This study identified 27 mutations, 
of which 13 were single nucleotide variants (predicted to truncate the protein) 
and 13 were insertion-deletion mutations. Lymphoma samples were matched 
with normal skin to assess for germ-line mutations and interestingly 21 samples 
had germ-line mutation identified which was predicted to affect TRAF3 
function. In total, 44.4% of B-cell lymphoma samples with a TRAF3 mutation 
had more than one mutation (somatic or germ line) predicted to affect TRAF3 
function. This study also looked at TRAF3 mutations in 148 cases of human 
DLBCL using Affymetrix SNP 6.0 software and identified 13 (8.9%) cases with 
deletions affecting TRAF3.  They then used FISH to confirm the deletion in five 
cases. RNA-sequencing data from 91 cases showed a significant reduction in 
TRAF3 expression in mutated individuals. 
 
Some veterinary studies have suggested that deregulated NFkB activity is also 
a feature of canine B-cell lymphoma (Rowell et al., 2011, Richards et al., 2013, 
Mudaliar et al., 2013). Mutations to the TRAF3 gene, which is involved in NFkB 
activity, have been shown in a number of studies assessing canine B-cell 
lymphoma (Bushell et al., 2015, Elvers et al., 2015). Richards et al (Richards et 
al., 2013) found that differences in NFkB pathway were among the variables 
that could be used to separate dogs into prognostically distinct groups, similar 
to human ABC DLBCL and GCB DLBCL. Genes involved in regulating NFkB activity 
have been found to be commonly mutated ABC BCL cases, which is consistent 
with the altered NFkB activity found on gene expression profiling. Mutations 
affecting NFkB activity include loss of function of the negative regulator 
TNFAIP3, activation on positive regulators including CARD11 and others (Bushell 
et al., 2015). Based on these findings, NFkB inhibition is a promising therapeutic 




Previous research at our institution used next generation sequencing (RNA-Seq) 
to assess the mutational status in canine lymphoma in 18 BCL and five TCL 
(Waugh, 2015). This work identified several gene variants that were 
proportionately more frequent in BCL. These included mutations in TRAF3, 
POT1, DDX3X and TBL1XR1, in which mutations were only identified in BCL 
samples. TRAF3 variants were unique in all cases and all mutations were within 
exons 9, 10 and 11. The majority of mutations identified in a previous study of 
TRAF3 mutations in canine BCL were also within these exons (Bushell et al., 
2015).  
 




TRAF3 is a TNF-receptor associated factor and is part of the CD40 signalling 
cascade which regulates proliferation, immunoglobulin class switching and 
apoptosis (Elvers et al., 2015). It is part of the tumour necrosis factor receptor-
associated factor (TRAF) family of cytoplasmic adaptor proteins (Moore et al., 
2015). TRAF3 signalling is used by a number of receptors, including TNF-
receptors, pattern recognition receptors, and several viral proteins (Moore et 




TRAF3 is considered a tumour suppressor gene and has been implicated in 
several tumours including several types of lymphoma, multiple myelomas, as 
well as other malignancies (Bushell et al., 2015). In the absence of stimulation, 
TRAF3 forms a complex with TRAF2, the E3 ubiquitin ligase cIAP1/2, and NFkB-
inducing-kinase (NIK). In this complex, cIAP1/2 targets NIK for degradation, 
which leads to inhibition of NFkappa-B activation. B-cell activating factor 
(BAFF) stimulation results in trimerized BAFF-receptors or CD40 recruiting 
cytoplasmic TRAF2 and TRAF3. This releases NIK from the TRAF2-TRAF3-cIAP1/2 
complex, leading to NIK accumulation in the cytoplasm. This leads to 
phosphorylation of I-kappa-B kinase alpha (IKKa), which subsequently causes 
the inactive NFkB2/p100 to convert to the active NFkB2/p52. This complex then 
forms dimers with RelB which translocate to the nucleus and induce the 
transcription of anti-apoptotic Bcl2 family proteins, ultimately leading to B-cell 
survival.  
 
TRAF3 also acts with other proteins to target MAP3K14 for degradation. It 
negatively regulates NFkB by targeting NIK for constant ubiquitisation and 
degradation (Bushell et al., 2015, Sun, 2011). NIK is then recruited by the 
TRAF2-cIAP1/2 ubiquitin ligase complex and degraded (Vallabhapurapu et al., 
2008). Therefore reduced TRAF3 activity leads to NIK stabilisation and an 




TRAF3 in dogs is found on chromosome 8 and is composed of 568 amino acids in 
11 exons. The TRAF3 protein has several domains. The N-terminal part of TRAF3 
has a really interesting new gene (RING)-type binding zinc domain and several 
zinc fingers (Qian Yin, 2009). The RING domain mediates the interaction 
between E2 ubiquitin conjugating enzymes and their substrates. Zinc finger 
domains mediate interactions between proteins and DNA, RNA, lipids and other 
proteins. The C-terminal part of TRAF3 can be divided into TRAF-N and TRAF-C 
domain. The TRAF-N domain includes two coiled coil regions which mediate the 
homo- and hetero-oligomerisation among TRAF family members. TRAF3 forms 
heterotrimers with TRAF2 (He et al., 2004) as part of its normal function. This 
TRAF trimerization enhances the otherwise weak interactions between the 
TRAF proteins and their substrates (Qian Yin, 2009). The TRAF-C domain 
contains a meprin and TRAF homology (MATH) domain which is necessary for 
receptor interaction and interactions with adaptor proteins (Qian Yin, 2009).  
 
TRAF3 mutations can have a dominant negative effect, meaning heterozygous 
mutations can cause phenotypic changes. Mutations to RING-type domain or 
zinc finger domain can competitively displace normal TRAF3 if the C-terminal 
TRAF3 domains on the mutated protein are normal. Mutations to the C-terminal 
TRAF3 domains can prevent normal TRAF3 recruitment (Force et al., 1997). 
 
Elvers et al (Elvers et al., 2015) found that TRAF3 alone is mutated in 30% of 
Cocker Spaniel and Golden Retriever B-cell lymphoma, and 30% and 50% of 
either or both TRAF3 and MAP3K14 are mutated in Cocker Spaniels and Golden 
Retrievers respectively.   
CHAPTER 1 
 33 
Aim of this study 
This study had two main aims. These were: 
1. To investigate the immunohistochemical characteristics of canine 
lymphoma using a variety of immunohistochemical markers, some of 
which have proven significance in human lymphoma subclassification, or 
other canine cancers, to see if this would assist in the subclassification 
of canine T-cell lymphoma in particular, and 
2. To investigate the prevalence and characteristics of TRAF3 mutations in 
canine B-cell lymphoma, and to assess dogs with other non-BCL diseases 






2 Materials & Methods 
2.1 Immunohistochemistry 
2.1.1 Samples 
Tissue from 59 canine patients diagnosed with lymphoma at centres throughout 
the UK were included. All samples were submitted to Veterinary Diagnostic 
Services (VDS, Glasgow, UK) for either full diagnostic assessment (histology and 
immunohistochemistry by VDS pathologists), or for immunophenotyping after 
initial histology was performed by a separate laboratory (Nationwide Laboratory 
Services, Leeds, UK). All samples had initial immunophenotyping (B-cell/T-cell) 
performed at our institute (VDS) and all had histopathology and/or 
immunophenotyping reports available for review. All samples were diagnosed 
as lymphoma and were immunophenotyped by immunohistochemistry by a 
board-certified pathologist (or resident under Specialist supervision). B-cell/T-
cell immunophenotyping involved immunohistochemistry with a panel of at 
least CD3 for T-cells and CD79a and/or Pax5 for B-cells, using standard IHC 
protocols. Samples were included if enough tissue remained for additional IHC 
to be performed. Unfortunately due to unexpected difficulties in optimising 
some of the IHC stains, some tissue samples did run out before the completion 
of the project. Samples were excluded if their lymphoma diagnosis and/or B-
cell/T-cell immunophenotype was ambiguous, or if there was insufficient 
sample for additional IHC to be run. 
 
2.1.2 Staining protocols used for IHC 
See table 2-1 for details of the antibodies used. Staining was performed by the 
Veterinary Diagnostic Services laboratory (University of Glasgow, UK). Staining 
protocols had previously been validated by the laboratory for c-Kit (Webster et 
al., 2007) and clusterin (Shafie et al., 2014). CD30 staining required numerous 
trials based on previous publications (Park et al., 2007, Pittaway et al., 2018, 
Stranahan et al., 2019, Hohsteter et al., 2014) before a successful technique 
was found by following the process used in a publication by Bauer et al (Bauer 





Staining was performed using a Dako Autostainer (Dako, Santa Clara, USA).  
 
2.1.2.1 Clusterin, c-Kit and CD30 protocols 
Clusterin and c-Kit staining was performed according to the following protocol: 
5m sections were cut, deparaffinized in xylene, rehydrated in graded ethanol, 
and rinsed in distilled water. Antigen retrieval was performed using 10 mM 
sodium citrate buffer pH 6.0 in an automated pressure cooker. The samples 
were loaded onto the autostainer (Dako). The buffer was rinsed and endogenous 
peroxidase activity was quenched with 5 minute blocking solution (Dako Real 
Peroxidase, Dako). The samples were incubated with the primary antibody at 
the appropriate dilution for 30 minutes at room temperature. Sections were 
washed and incubated with the conjugated antibody. The immunocomplexes 
were detected with 3,3-diaminobenzidine (Dako K5007 DAB) substrate 
chromogen. Samples were counterstained with haematoxylin. Sections were 
dehydrated using a series of degraded alcohol baths and mounted in synthetic 
resin. 
 
CD30 staining was performed by an identical procedure aside from the samples 
being incubated with the primary antibody for 16 hours at four degrees Celsius. 
 
2.1.2.2 CXCR5, PD-1 and ALK protocols 
The protocol outlined above was followed however the following variations 
were attempted: 
• Antigen retrieval was performed on different samples using the following 
techniques: 
1. Heat induced epitope retrieval using Menarini Access Retrieval Unit. 
Buffers used: Sodium Citrate pH6, or EDTA pH8 or pH9, treated for 1 min 
40 sec at 125⁰C full pressure. 
2. Enzymatic antigen retrieval using Proteinase K RTU (Dako). 
• The following antibody dilutions were trialled: 




2.1.3 Evaluation and scoring system used for clusterin IHC 
Nascimento et al (Nascimento et al., 2004) previously described a grading 
system which examined the staining pattern of clusterin (golgi, membranous, 
cytoplasmic) and then divided cases into 3 categories (focal: <25%, 
intermediate: 25-75%, diffuse: >75%) based on the proportion of neoplastic cells 
showing golgi staining over the entire field. This system was adapted for this 
study. A further category was added (rare: <1% cells) due to the low numbers 
of positive cells in some samples. The term “focal” was changed to “mild” as 
“focal” suggests a geographic concentration of positive cells within the 
samples, whereas in all cases the positive cells were interspersed throughout 
the sample. 
 
Samples were assessed by finding a representative area of neoplastic cells, if 
possible distant from any areas of stromal/background staining. Between 5-10 
40x high power fields (hpf) were assessed in each case. All samples showed 
varying degrees (ranging from very mild to mild) of granular nuclear and 
cytoplasmic staining. This was not considered to be positive staining. 
 
Grading scheme used: 
• Negative: No lymphoma cells positive. 
• Rare: <1% lymphoma cells positive 
• Mild: <25% lymphoma cells positive 
• Intermediate: 25-75% lymphoma cells positive 
• Diffuse: >75% lymphoma cells positive. 
 
Samples also had their pattern of staining (golgi, membranous, cytoplasmic) 




2.1.4 Evaluation of c-Kit IHC 
Samples were categorised as positive or negative. Samples were considered 
positive if any of the neoplastic cells showed specific staining. Positive samples 
had the staining pattern (golgi, membranous, cytoplasmic), intensity (weak, 
moderate, strong), and geographic distribution (interspersed individual cells, 
regionally diffuse, diffuse) recorded. Samples were categorised as “regionally 
diffuse” if all lymphoma cells within a focal geographic region were positive 
while the remainder of the neoplastic cells outside this area were negative. 
 
2.1.5 Evaluation of CD30 IHC 
Samples were categorised as positive or negative. Samples were considered 
positive if any of the neoplastic cells showed specific staining. Positive samples 
had the staining pattern (golgi, membranous, cytoplasmic), intensity (weak, 
moderate, strong), and geographic distribution (interspersed individual cells, 
regionally diffuse, diffuse) recorded. Samples were categorised as “regionally 
diffuse” if all lymphoma cells within a focal geographic region were positive 
while the remainder of the neoplastic cells outside this area were negative. 
 
2.1.6 Evaluation of ALK, CXCR5 and PD-1 IHC 
Human Hodgkin’s lymphoma, human tonsil and canine tonsil were used for 
antibody optimisation with standard methods and then modifications as 




Table 2-1. Antibodies used for immunohistochemistry. 
 
















16 hours at 
4 degrees C 
Clusterin 
(ab104652) 












Rabbit Human n/a Abcam n/a  
PD1 
(ab52587) 
Mouse Human n/a Abcam n/a  
ALK (D5F3) Rabbit Human n/a Cell Signalling 
Technology 
n/a  




2.2 TRAF3 mutation analysis 
2.2.1 Samples 
Samples were collected from canine patients with suspected/confirmed 
lymphoma presenting to the oncology service at the Small Animal Hospital, 
University of Glasgow, UK between 2010 and 2014. Samples included tissue 
biopsies for histopathology and tissue fine-needle aspirates. Aspirates had DNA 
extracted within 24 hours of collection and samples were stored frozen (-80 
degrees Celsius) or, if submitted for histopathology, were formalin-fixed 
paraffin-embedded (FFPE). Matched non-tumour DNA samples were obtained 
from blood samples from the same patient. All matched blood sample were 
assessed cytologically by a clinical pathologist and had no cytological evidence 
of circulating neoplastic cells. Samples were submitted to Veterinary Diagnostic 
Services, University of Glasgow, UK for pathological assessment as part of 
routine diagnostic evaluation or collected post-mortem. Lymphoma diagnosis 
was based on cytology or histopathology results in combination with polymerase 
chain reaction for antigen receptor gene rearrangement (PARR) results, flow 
cytometry, and/or immunohistochemistry. PARR was performed at the 
University of Glasgow as previously described (Waugh et al., 2016). 
Immunophenotyping by flow cytometry was performed at the University of 
Glasgow using a panel of antibodies comprising: CD5, CD21, CD45, CD3, CD4, 
CD8, CD34, CD79a, MHC II, MAC387, and CD14. Immunohistochemistry antibody 
panels were decided by the attending pathologist, with all including at 
minimum Pax5 and/or CD79a, and CD3. DNA samples from non-lymphoma cases 
(from peripheral blood, lymph node aspirates, or lymph node FFPE tissue) were 
collected from samples submitted to the VDS from canine patients with a 





Sample collection and subsequent research activity were approved by the 
Faculty of Veterinary Medicine Ethics and Welfare Committee (License number: 
1a/09; 32a/15) and written consent was obtained from owners at the time of 
initial presentation. The TRAF3 polymerase chain reactions (PCR) performed in 
this study used DNA which had been previously extracted from blood and tissue 
samples.  
2.2.2 DNA extraction 
DNA was purified from blood and unfixed samples using DNeasy Blood and Tissue 
Kits (Qiagen, Manchester, UK), and from FFPE samples using QIAamp DNA FFPE 
Tissue Kit (Qiagen) according to the manufacturer’s instructions. Briefly, FFPE 
samples had excess paraffin trimmed and one to eight 5-10um thick sections 
were cut. The sections were placed in a tube with xylene, vigorously vortexed, 
centrifuged, and supernatant removed. The pellet was dehydrated and 
resuspended in buffer ATL (Qiagen). Proteinase K (Qiagen) was added and the 
sample vortexed. The sample was incubated for one hour at 56 degrees Celsius, 
then a further hour at 90 degrees Celsius. Buffer AL (Qiagen) and ethanol were 
added and the sample immediately vortexed. The homogenate was transferred 
to a QIAamp MinElute column and centrifuged to bind the DNA to the column 
membrane, and prepared by passing Buffers AW1 (Qiagen) and AW2 (Qiagen) 
through the membrane with serial centrifugations. Buffer ATE (Qiagen) was 
then applied to the membrane for 5 minutes before the final centrifugation 
which eluted the DNA into the resulting flow through. For blood and unfixed 
samples, 20L proteinase K was added to the blood or homogenated tissue 
sample. 200L buffer AL (Qiagen) was added and incubated at 56 degrees 
Celsius for 10 minutes, then 200L ethanol was added. The resulting mixture 
was pipetted onto a DNeasy Mini spin column and centrifuged to bind the DNA 
to the spin column. The DNA was prepared by serial centrifugations with Buffer 
AW1 followed by Buffer AW2. The DNA was then eluted by centrifugation after 





2.2.3 Polymerase chain reaction (PCR) 
2.2.3.1 Primer design 
Primers were designed using Integrated DNA Technologies® (IDT, Leuven, 
Belgium) online PrimerQuest® tool. Primers were designed to amplify exons 9, 
10 and 11 of the canine TRAF3 gene (Table 2-2). Exons were selected based on 
the location of the majority of variants identified in previous studies (Elvers et 
al., 2015, Bushell et al., 2015, Waugh, 2015). Primers were synthesised by IDT 






Table 2-2. TRAF3 primers 
Exon Direction Primer Sequence Amplicon 
size (bp) 
9 Forward 5’- ACC AGA ACT TCC ATT TCC TGT AT 
-3’ 
387 
Reverse 5’- CAG CTC ACT GAG AAT ACC CAA A 
-3’ 
10 Forward 5’- CAG GTA GAG ACC AGG ACA CA -3’ 330 
Reverse 5’- TAA CTA GCC GGT GTC TCT TCT -
3’ 
11 Forward 5’- CCA GCC TTC CTG ACA CTT AC -3’ 666 
Reverse 5’- AGA TGC CTT CTG AAT CC -3’ 




2.2.3.2 Reaction conditions 
Amplification was performed in a 25µL reaction volume consisting of: 0.1 units 
of Invitrogen AccuPrime TAQ DNA Polymerase, High Fidelity (ThermoFisher 
Scientific, Paisley, UK); Invitrogen™ Accuprime™ PCR Buffer II (ThermoFisher 
Scientific); 0.5 µM forward primer; 0.5 µM reverse primer; and 20 ng DNA 
template. Template controls contained DNA-ase free water instead of template 
DNA and were included after every seven samples. Samples previously shown 
to contain amplifiable DNA served as positive controls. 
 
Thermal cycling was conducted using a BIO-RAD C1000 Touch™ Thermal Cycler 
(BIO-RAD, Kidlington, UK) under the following reaction conditions: initial 
activation at 94°C for two minutes; 40 cycles of 94°C for 15 s, 58°C for 30 s, 
68°C for 30 s; and 68°C for seven minutes. 
 
2.2.3.3 Gel electrophoresis 
Products were visualised using one percent agarose gel electrophoresis. The 
agarose was prepared by completely dissolving one gram of agarose powder in 
tris/borate/EDTA (TBE) buffer solution. Two microlitres of ethidium bromide 
(10mg/ml) were added to the solution and it was placed in a mould with 10-30 
wells. Once set, the gel was placed in a gel box and submerged in TBE solution. 
Each sample was prepared by combining 9uL of sample and 1uL of loading gel. 
A DNA ladder was placed in the lateral most well and each test well was filled 
with 10uL of solution. The gel was run at 80V for ~one hour until the visible 
loading gel had run ~75% down the gel. The gel was then photographed under 
UV light and size of products estimated by comparing to the ladder solution in 




2.2.3.4 DNA Purification 
PCR products were purified to remove residual primers and nucleotides using 
the MinElute PCR Purification Kit (Qiagen) in accordance with the 
manufacturer’s instructions. Briefly, the PCR Reaction mixed was combined 
with Buffer PB (Qiagen). This mixture was placed in a MinElute column and 
bound to the membrane by centrifugation. The sample was washed by 
centrifugation with Buffer PE (Qiagen). Samples were then eluted in 20-40 µL 
of distilled water. 
 
2.2.3.5 Sequence Analysis 
Direct Sanger Sequencing of purified amplicons was performed by Source 
Bioscience (Bellshill, UK). Sequence files were imported into CLC Genomics 
Workbench 6.5.1 (Qiagen) software. Chromatograms were visually inspected, 
and samples with poor quality traces were re-sequenced. Contiguous sequences 
were made by aligning forward and reverse reads. These were then compared 
against the canine TRAF3 reference nucleotide sequence CanFam 3.1(Hoeppner 
et al., 2014) and sequence variants identified. Mutated alleles were translated 
in silico to determine the effect of variants. Mutations were classed as 






3.1 Use of immunohistochemistry in lymphoma to identify 
specific subpopulations 
In this part of the study, a range of antibodies were used on a broad range of 
canine lymphoma samples to see if any subgroups could be identified. The 
initial panel of antibodies were selected based on their role in subtyping human 
TCLs (CXCR5, PD-1, ALK, CD30) as there is currently a particular lack of canine 
TCL subtyping. The tissue samples chosen for the project were mainly TCL with 
a smaller number of BCL included for comparison. When it became clear that 
some of the antibodies could not be optimised for canine tissue within the 
timeline of the project, other antibodies were selected for assessment. These 
were: clusterin, which may have a role in subtyping TCL in poorly differentiated 
cases, and c-Kit, which currently does not have a role in human lymphoma, 
although it has not been assessed in a broad selection of canine lymphoma 
samples. 
 
Successful staining was achieved with clusterin, c-Kit and CD30 and 
interpretation of the staining is detailed below and in tables 3-1 and 3-2.   
 
Fifty-nine canine lymphoma samples were included in the study. These included 
46 TCL and 13 BCL. Of the TCL samples, 9/46 were considered low grade (seven 
TZL, two low grade gastrointestinal TCL), and 37/46 were considered high grade 
(16 nodal PTCL-NOS, six cutaneous non-epitheliotropic TCL, five high grade 
gastrointestinal TCL, two cutaneous epitheliotropic TCL, two mediastinal TCL, 
two subcutaneous TCL, and one each of ocular, mesenteric, testicular and 
muscular TCL). Of the BCL samples 12/13 were considered high grade (10 nodal 
DLBCL, one high grade gastrointestinal, one high grade cutaneous non-





Overall, 21 samples were positive for at least one of the antibodies assessed. 
18/21 were TCL and 3/21 were BCL; 20/21 were only positive for a single 
antibody. One case (case 28 – high grade subcutaneous TCL) was positive for 
both CD30 and clusterin. There was no obvious correlation between positivity 
for the novel antibodies and morphological subtype. Of positive samples, 15/18 
TCL cases were high grade and 3/18 were low grade, and 2/3 BCL cases were 
high grade and 1/3 were low grade. 
 
3.1.1 ALK, CXCR5 and PD-1 IHC could not be optimised 
Despite testing a range of IHC protocols (including changing antibody dilution 
and antigen retrieval methods), antibody marker optimisation on canine tissue 
was not possible for ALK, CXCR5 and PD-1 within the timeframe of the project, 
so these antibodies could not be assessed. With all markers and using all the 
IHC techniques outlined in 2.1.2.2 the canine control tissue was universally 
negative, so these markers were not further investigated. If more time had 
been available for the project, more attempts would have been made to 
optimise these markers for canine tissue. Several additional methods could 
have been pursued, including using tissue which had been more recently 
formalin fixed (as prolonged formalin fixation can degrade tissue antigens), or 
trialling additional canine control tissues (for example for ALK, trying to obtain 
samples of the previously reported CD30 positive ALCL cases, as these may have 
been positive if canine ALK expression is similar to human ALK expression). Also, 
we could have assessed the expression of the target protein in the samples using 
RT-PCR or RNA-seq. This would have allowed us to confirm the presence of the 
target protein and then we could have focussed our attempts on those samples 
with the highest levels of expression, as these would be most likely to be 
positive. We could also have trialled additional antigen retrieval methods and 
staining methods. For example, our CD30 protocol involved incubating the 
samples at 4 degrees Celsius for 16 hours. This method was pursued due to a 
previous publication reporting this method to be effective. Unfortunately we 
were not able to trial prolonged incubations or different temperatures for all 




3.1.2 Clusterin IHC  
Fifty-six samples were stained with clusterin and a summary of clusterin 
positive patient and staining characteristics is shown in Table 3-3. See Fig. 3-1 
for positive control sample. 
 
14/56 (25%) samples assessed were considered positive. These included 11/43 
(26%) TCL and 3/13 (23%) BCL. Results were not available for three TCL cases 
as insufficient tissue samples were available for staining.  
 
Of the positive TCL cases, 3/11 were low grade, all of which were TZL, making 
3/7 TZL cases assessed positive for clusterin. The remaining 8/11 positive cases 
were high grade, and included four PTCL-NOS, two cutaneous non-
epitheliotropic TCL, and one each of high grade gastrointestinal and 
subcutaneous TCL. Of positive BCL cases, 2/3 were DLBCL and 1/3 was low 
grade splenic mantle cell lymphoma. No obvious patterns of staining could be 
linked to the histopathological grade or morphological diagnoses. 
 
All positive samples had a golgi cytoplasmic staining pattern. No other staining 
pattern was seen in neoplastic cells. All samples had interspersed positive cells. 
In no samples was there diffusely positive staining. Nor were there any samples 
with geographic areas of diffuse staining. 9/14 samples were graded as rare 
staining (<1% neoplastic cells) and 5/14 were graded as mild staining (<25% 
neoplastic cells). Staining intensity was moderate and strong in 12/14 and 2/14 
samples respectively. An example of a positive case is shown in Fig. 3-2. 
 
In one case of testicular lymphoma, the normal testicular structures adjacent 
to the tumour showed positivity. Testicular clusterin staining has previously 




A common feature noted in almost all samples was a fine granular, 
predominantly nuclear (with a lesser degree of cytoplasmic), staining (see Fig. 
3-3). Given the ubiquity of this staining pattern, and the fact that it appeared 
independent of other staining patterns, it was not considered a positive result. 
Subjectively, the BCL seemed to have a greater intensity of this diffuse fine 
granular staining than the TCL samples. 
 
3.1.3 C-Kit IHC 
Fifty-eight samples were stained with c-Kit antibody and a summary of c-Kit 
positive patient and staining characteristics are shown in Table 3.4. See Fig. 3-
4 for positive control sample. 
 
5/58 samples were considered positive. All five were TCL (5/46; 11%). See Fig. 
3-5 and Fig. 3-6 for examples of positive staining. One BCL sample did not have 
results available due to insufficient sample available for staining.  
 
All positive cases were high grade TCL. 2/5 were high grade gastrointestinal 
lymphomas (making 2/5 of the included high grade gastrointestinal lymphomas 
positive for c-Kit), and there was one each of cutaneous non-epitheliotropic 
TCL, epitheliotropic TCL, and nodal PTCL-NOS. No obvious patterns were 
identified between c-Kit positivity and morphological diagnosis, however the 
20% prevalence of c-Kit positive high grade gastrointestinal TCL is interesting 
and warrants further investigation in a larger cohort of these cases. 
 
The proportion of neoplastic cells staining varied between samples: 3/5 samples 
showed diffuse staining (ie all neoplastic cells were positive); 1/5 showed 
interspersed positive cells; and 1/5 showed diffusely positive cells limited to 
only two areas of the slide. This case (sample 34) involved 23 intestinal pinch 
biopsy fragments on the slide (see Fig. 3-7a). All fragments had varying numbers 
of CD3 positive neoplastic lymphocytes, however in only two fragments were 
the lymphoma cells c-Kit positive. In these fragments the lymphoma cells 




The staining pattern observed also varied between positive samples, and 
included membranous (1/5), cytoplasmic (3/5), and golgi (1/5).  
 
The staining intensity was strong in 1/5, moderate in 1/5 and weak in 3/5 
samples. 
 
3.1.4 CD30 IHC 
Forty-six samples were stained with CD30 antibody and a summary of positive 
patient and staining characteristics are shown in Table 3-5. See Fig. 3-8 for 
positive control sample. 
 
3/46 samples were considered positive and all were TCL (3/46; 6.5%). All 
positive cases were high grade TCL. The positive cases included on each of: 
nodal PTCL-NOS, high grade subcutaneous TCL, and cutaneous non-
epitheliotropic lymphoma. Three cases of TCL did not have results available 
due to insufficient sample for staining. 
 
Only one sample (case 33 – high grade cutaneous non-epitheliotropic TCL) 
showed diffuse staining (see Fig. 3-9). The other two positive samples only had 
interspersed positive cells (<1% of all neoplastic cells). In one sample 
(subcutaneous TCL) the positive cells were present interspersed throughout the 
sample however the proportion of positive cells was increased in some specific 


















nodular Stated Diagnosis 
Clusterin C-Kit CD30 
T-
cell 1 11.7 M Retriever LN (SMLN) 
SMALL-
INTERMED Nodular TZL 
   
 




LARGE n/a  
   
 
3 13 F 
Staffordshire 
bull terrier Cutaneous  n/a Cutaneous T-cell 
+   
 
4 9.6 MN 
Cocker 
spaniel LN INTERMED Nodular TZL 
+   
 




LN) LARGE Diffuse PTCL-NOS 
   
 
6 7.3 FN Cairn terrier 
LN (Popliteal 
and SMLN) INTERMED Diffuse PTCL-NOS 
  + 
 
7 8.3 F Inuit dog 
LN (Popliteal 
LN) LARGE Nodular TZL 
   
 
8 12 F Border collie Cutaneous LARGE n/a 
Cutaneous (non-
epitheliotropic) 
 +  
 





(duodenum) LARGE n/a 
High-grade GI T-cell 
lymphoma 
+   
 
10   FN 
Cocker 
spaniel LN LARGE Diffuse PTCL-NOS 




11 4 M 
English 
springer 
spaniel LN (SMLN) LARGE Diffuse PTCL-NOS 
   
 






LARGE Diffuse PTCL-NOS 
   
 
13 8 F WHWT 
Subcutaneous 
mass LARGE n/a  
   
 14 6.3 M Cross LN (SMLN) SMALL Nodular TZL    
 
15 8.7 MN 
Springer 
spaniel 
LN (PS and 
popliteal LN) LARGE Diffuse PTCL-NOS 
   
 16 8 FN Bullmastiff LN (PSLN) LARGE Diffuse PTCL-NOS    
 
17 5 MN Labrador 
LN (popliteal 
LN)  Diffuse PTCL-NOS 
+   
 




INTERMED Nodular TZL 
   
 
19 11 F Bull dog 
LN 
(mediastinal) INTERMED Diffuse Mediastinal lymphoma 
   
 
20 6.5 FN Cross LN (SMLN) 
INTERMED-
LARGE Diffuse PTCL-NOS 
+   
 




LARGE n/a  
   
 




mass LARGE n/a  
   
 
23 3 MN 
Cocker 
spaniel LN (PSLN) LARGE Diffuse PTCL-NOS 
   
 











25 8.8 F Cross 
LN (popliteal 
LN) INTERMED Diffuse PTCL-NOS 
   
 
26 7.3 M Labradoodle LN (PSLN) 
SMALL-
INTERMED Diffuse PTCL-NOS 
+   
 
27 11.3 FN Labrador Cutaneous n/i n/a 
Cutaneous (non-
epitheliotropic) 
   
 
28 10.3 M WHWT Subcutaneous 
INTERMED-
LARGE n/a  
+  + 
 29 13.5 MN Cross LN (SMLN) LARGE Diffuse PTCL-NOS    
 
30 10.2 F Boxer Mucocutaneous n/i n/a 
Epitheliotropic T-cell 
lymphoma 
 +  
 
31 12 M 
Cocker 
spaniel LN (PSLN) SMALL Diffuse PTCL-NOS 
   
 
32 9.2 F Boxer 
Cranial 
mediastinal 
mass INTERMED Diffuse Mediastinal lymphoma 
   
 
33 4.2 F 
Dogue de 






  + 
 






High-grade GI T-cell 
lymphoma 
 +  
 
36 3 FN Weimaraner Muscle  
 Intermediate-
large n/a  
   
 





High-grade GI T-cell 
lymphoma 
   
 38 11.7 MN Labrador LN (PSLN) INTERMED Nodular TZL +   




41 7.8 M Labrador 
Large 
intestinal mass 
(colon) LARGE n/a 
High-grade GI T-cell 
lymphoma 
 +  
 
42 7.8 FN Labrador Small intestine SMALL n/a 
Low grade GI T-cell 
lymphoma 
   
 




+   
 










   
 
46 9.8 M 
Golden 
retriever 
LN (SM and 
PSLN) SMALL Nodular TZL 
+   
 
47 12.3 M 
Staffordshire 
bull terrier LN (SMLN) LARGE Diffuse PTCL-NOS 
 +  
 
48 8.5 M Labrador Stomach INTERMED  n/a 
Low-grade GI 
lymphoma 
   
 
49 10.3 FN Shih-tzu Duodenum LARGE  n/a 
Epitheliotropic T-cell 
lymphoma 
   
B-
cell 51 10 MN WHWT LN LARGE  Diffuse DLBCL 
   
 
52 4.6 M Border collie LN 
INTERMED-
LARGE Diffuse DLBCL 
   
 
54 11 M Schnauzer 
LN (popliteal 
LN) LARGE  Diffuse DLBCL 
   
 
55 11 MN Cross LN 
INTERMED-
LARGE Diffuse DLBCL 
   
 
56   F 
Belgian 
shepherd LN (SMLN) 
INTERMED-
LARGE Diffuse DLBCL 
   
CHAPTER 3 
 54 
 57 10 MN Irish setter LN LARGE Diffuse DLBCL    
 
58 10.7 F 
Jack Russel 
terrier LN INTERMED  Diffuse DLBCL 
+   
 
59 4.9 F 
Miniature 
schnauzer LN (PSLN) LARGE Diffuse DLBCL 
   
 
60 12.1 MN Schnauzer Stomach mass LARGE n/a 
High-grade GI B-cell 
lymphoma 
   
 61 9.4 MN Collie Spleen LARGE n/a Mantle cell lymphoma +   
 
62 11.4 MN Border collie LN (PSLN) 
INTERMED-
LARGE Diffuse DLBCL 
   
 








   
 
64 5 FN Weimaraner Tonsil 
INTERMED-
LARGE Diffuse DLBCL 
+   
*Sample ID numbers assigned before samples excluded - 59/64 samples were used in final study.  
n/i: not included in report; n/a: not applicable; M: male; ME: male entire; F: female; FE: female entire; LN: lymph node; SMLN: 
submandibular lymph node; PSLN: prescapular lymph node; TZL: T-zone lymphoma; PTCL-NOS: peripheral T-cell lymphoma – not 




Table 3-2. Summary of IHC staining patterns in positive samples of canine lymphoma. 
Antibody Disease Number positive Staining patterns 






BCL (n=13) 0/12 (1 not available)  
CD30 TCL (n=43) 3/43 (3 not available) 1 rare interspersed, 1 
majority negative with a 
focal geographic area of 
neoplastic cells with 100% 
positivity, 1 diffuse 
BCL (n=13) 0/13  
Clusterin TCL (n=43) 11/43 (3 not available) 4 Mild, 7 rare 
BCL (n=13) 3/13 1 Mild, 2 rare 









Lymphoma details Staining characteristics 
TCL 3 Cutaneous Rare moderate golgi 
4 TZL Rare moderate golgi 
9 High grade GI (duodenal) Mild strong golgi 
17 Nodal PTCL-NOS Rare moderate golgi 
20 Nodal PTCL-NOS Mild moderate golgi 
26 Nodal PTCL-NOS Rare moderate golgi 
28 Intermediate-large cell, subcutaneous Mild moderate golgi 
38 TZL Rare moderate golgi 
40 Nodal PTCL-NOS Rare moderate golgi 
44 Large cell cutaneous non-epitheliotropic Mild moderate golgi 
46 TZL Rare moderate golgi 
BCL 58 Nodal DLBCL Rare moderate golgi 
61 Splenic mantle cell lymphoma Rare moderate golgi 
64 Tonsilar DLBCL Mild strong golgi 














Table 3-4. C-Kit IHC: Summary of positive samples. 
Sample 
number 
Lymphoma details Staining characteristics 
8 Large cell cutaneous non-epitheliotropic TCL Diffuse moderate golgi staining 
30 Mucocutaneous epitheliotropic TCL Diffuse weak cytoplasmic 
34 High grade GI TCL 2/21 biopsies with diffuse weak cytoplasmic (see 
picture) 
41 High grade GI TCL Diffuse strong membranous 
47 Nodal PTCL-NOS Interspersed ~30% of cells weak cytoplasmic 





Table 3-5. CD30 IHC: Summary of positive samples. 
Sample 
number 
Lymphoma details Staining characteristics 
6 Nodal PTCL-NOS Interspersed (<1%) population with strong cytoplasmic 
28 Intermediate-large cell, subcutaneous TCL Interspersed (<1%) population with weak-moderate 
membranous-cytoplasmic staining. Most positive cells 
within a single geographic region (up to 10% of 
neoplastic cells positive in densest region). 
33 Intermediate-large cell, cutaneous non-
epitheliotropic TCL 
Diffuse moderate membranous 




Fig. 3-1. Clusterin IHC control sample: canine spinal cord (40x magnification) 
with clusterin immunostaining. The neurons (arrows) show punctate 






Fig. 3-2. Clusterin (40x magnification): Large cell nodal T-cell lymphoma 
(case 40). Region of highest number of positive cells showing moderate golgi 







Fig. 3-3. Clusterin (40x magnification): Non-specific fine granular staining 






Fig. 3-4. C-Kit control sample: canine mast cell tumour (20x magnification) 










Fig. 3-6. C-Kit (40x magnification): Case 47, weak interspersed (~30% 





Fig. 3-7. C-Kit staining on intestinal pinch biopsies (case 34): a) unmagnified 
view of slide showing only 2 pinch biopsies with positive stain (arrowheads), 
b) non-staining area with negative staining in all neoplastic cells and only 
scattered positive mast cells (arrows) (10x magnification), c) positive area of 






Fig. 3-8. CD30 control sample: canine mast cell tumour (40x magnification) 












In this part of the study, the TRAF3 gene was assessed in a cohort of dogs with 
B-cell lymphoma to confirm the high prevalence of TRAF3 mutations found in 
previous studies (Bushell et al., 2015, Waugh, 2015) and characterise these 
mutations. We also assessed a cohort of dogs with non-BCL diseases (including 
four with TCL) to see if TRAF3 mutations were specific to BCL, or if they 
occurred with other conditions. Unfortunately, the BCL cases had varied 
treatments and incomplete records so it was not possible to correlate TRAF3 
analysis with patient outcomes or specific BCL subtypes. 
 
3.2.1 Patients 
Forty-nine patients were included in the study; these comprised 28 cases with 
lymphoma (24 cBCL, four cTCL) and 21 cases with non-lymphoma diseases (see 
Table 3-6 and Table 3-7). Four cBCL samples did not have sufficient sample 
available for TRAF exon 9 sequencing (all other sequencing was performed), so 
an additional four cBCL cases were recruited for TRAF3 exon 9 sequencing 
alone, giving a total of 53 cases for TRAF3 exon 9 (28 cBCL).  
 
Eleven lymphoma samples (10 cBCL, one cTCL) had matched non-tumour 
samples for comparison to determine whether mutations were somatic or 
germline.  Nineteen lymphoma samples (15 cBCL, four cTCL) had RNA-Seq data 
available (Waugh, 2015) for comparison. The age of patients ranged from 1.1 
years to 14.5 years (median 7.5 years). Twenty-two breeds and eight crossbreed 
dogs were included, and no breeds were overrepresented. 
 
Fig. 3-10 shows an example of PCR product on an agarose gel to confirm the 
product was of the expected size. Fig. 3-11 shows chromatograms and three 




3.2.2 Sequencing/Mutation analysis 
In total three exons from TRAF3 were sequenced based on the location of 
mutations in previous RNA-seq data (Waugh, 2015) and in previous publications 
(Bushell et al., 2015, Elvers et al., 2015). In six individual cases unsatisfactory 
DNA amplification and/or DNA sequencing data was obtained for one of the 
three exons sequenced (five TRAF3 exon 9, one TRAF3 exon 11). Since TRAF3 
exon 9 was predominantly affected by this, an additional four cBCL cases were 
recruited for TRAF3 exon 9 sequencing alone, giving a total of 28 cBCL cases 
which had at least partial TRAF3 sequencing. 
 
Eleven deleterious mutations of TRAF3 were found in 10 of 24 cBCL patients, a 
prevalence of 36%. No deleterious mutations were identified in cTCL or non-
lymphoma cases. The mutations identified are described in Table 3-8. One 
patient had two deleterious mutations identified.  
 
Most (9 of 11) deleterious mutations were frameshift mutations, leading to a 
change in the downstream amino acid sequence and premature termination of 
the translation, causing truncation of the protein. One further mutation was a 
nonsense mutation causing immediate termination of translation and truncation 
of the protein. The final mutation was an in-frame deletion of 12 base pairs 
(four amino acids). Protein modelling was not performed, however this 
mutation was assumed to be deleterious. Fig. 3-12 shows the location of the 
mutations on the TRAF3 protein, and the protein domains impacted. 
 
Five of 10 dogs with a deleterious TRAF3 mutation had matched non-tumour 
DNA. In four patients no mutation was identified in the matched tissue, 
indicating the mutations were somatic. In one dog with a frameshift mutation 
the wild-type allele was not detected (loss of heterozygosity), and an identical 




Of the 10 patients with deleterious mutations, RNA-Seq data was available for 
six for comparison. In two of the six patients, Sanger sequencing detected 
mutations which had not been identified by RNA-Seq. In the remaining four 
patients, the mutations identified in RNA-seq and Sanger sequencing were 
identical. 
 
In addition to the above mutations, 39 instances of non-deleterious 
(synonymous) variants were identified in 29 patients. These were spread across 
disease types, with a mutation identified in 15/28, 3/4, and 13/21 cBCL, cTCL 
and non-lymphoma cases respectively. Ten patients had two separate 
synonymous variants. Of the ten patients with a deleterious mutation, five also 
had synonymous variants. Four separate synonymous variants were detected, 
of which three had been identified previously (see Table 3-9). Since these 
variants were found in a variety of disease types including non-lymphoma cases, 
they likely represent polymorphisms. This is supported by the finding that the 
same synonymous variant was present in the non-tumour DNA (germline) in six 
of seven cases with matched DNA samples. In the final case, the synonymous 
variant was only identified in the lymphoma sample. In this case the wild-type 





Table 3-6. Canine B-cell lymphoma (cBCL) and canine T-cell lymphoma (cTCL) cases included in the TRAF3 study. 
Case 
group 






cBCL (n= 28) Cytology, flow cytometry and PARR 
(n= 20) 
Histology, IHC, PARR and flow 
cytometry (n= 4) 
Cytology and PARR (n= 2) 
Histology, IHC and PARR (n= 1) 








Cytology, flow cytometry and PARR 
(n=2) 
Histology, IHC and PARR (n=1) 
Lymph node 
aspirates (n=4) 
TZL (n=1) Histology, IHC, flow cytometry and 
PARR (n=1) 




Table 3-7. Non-lymphoma cases included in the TRAF3 study. 
Diagnosis (n=21) Samples for DNA extraction 
Lysosomal storage disease (n=1) FFPE lymph node 






Bone marrow aspirate 
Glaucoma (n=2) Peripheral blood (n=2) 
Idiopathic epilepsy (n=1) Lymph node aspirate  
Idiopathic immune-mediated 
polyarthritis (n=2) 
Lymph node aspirate (n=2) 
Allergic skin disease (n=1) Peripheral blood  
Portosystemic shunt (n=1) Peripheral blood  
Idiopathic/infectious lymphadenopathy 
which resolved with antibiotics (n=1) 
Lymph node aspirate  
Arrhythmogenic right ventricular 
cardiomyopathy (n=1) 
Lymph node aspirate  
Inflammatory bowel disease (n=1) FFPE intestinal biopsy 
Polyneuropathy (n=1) Lymph node aspirate  
Lymph node lipomatosis (n=1) FFPE lymph node 
Non-neoplastic reactive 
lymphadenopathy (diagnosis based on: 
histopathology and PARR [n=1], 
histopathology and IHC [n=1], 
histopathology, IHC, and PARR [n=1], 
cytology and PARR [n=1]) 
FFPE lymph node (n=3) 
Lymph node aspirate (n=1) 
FFPE, formalin-fixed paraffin-embedded; IHC, immunohistochemistry; PARR, PCR for antigen receptor rearrangement. 
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Fig. 3-10. Two exon 11 samples visualised under UV light on one percent 
agarose gel. The size of the two positive samples is estimated at ~550 base 
pairs based on the DNA ladder on the right. This is consistent with exon 11 
sequencing.  
  




Fig. 3-11. Example mutations as depicted on sequencing chromatograms (CLC 
Workbench). A) Heterozygous C deletion (asterisk) resulting in frameshift, B) 
heterozygous C-T nonsense mutation (arrow), C) homozygous G-A synonymous 
variant (arrowhead). The reference sequence is depicted at the top of each 
example. The coloured lines represent the fluororescent signal detected for 
each nucleotide (red: T, blue: C, black: G, green: A). The height of each 
coloured spike represents the relative intensity of the signal. By visually 
inspecting the chromatogram, it is possible to determine what abnormality 




Table 3-8. Deleterious TRAF3 mutations in canine B-cell lymphoma. 

















9 8:70782999 T-deletion Frameshift Heterozygo
us 
Ile302MetfsTer20 TRAF  Yes  
9 8:70782945 A-T point Nonsense  Heterozygo
us 
Lys286Ter TRAF N Yes rs851689319 






Leu317ProfsTer9 TRAF N NT  
9 8:70783003  A-insertion Frameshift Wild-type 
allele ND 















CC Y No  
11 8:70789277 A-deletion Frameshift Heterozygo
us 










Val477_His480del MATH  NT  
11 8:70789530 TC-insertion Frameshift Heterozygo
us 
Ala510AlafsTer14 MATH N NT  
11 8:70789589  A-deletion Frameshift Wild-type 
allele ND 
Lys549LysfsTer9 MATH  Yes  
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11a 8:70789131 C-deletion Frameshift Heterozygo
us 
Arg397AlafsTer21 MATH N NT  
Y, yes; N, no; NT, not tested; CC, coiled-coil domain; MATH, meprin and TRAF homology domain; NGS, next generation sequencing; 
NT, not tested; ND, not detected. 
a Same dog. 
b Mutation detected in a homologous location in human melanoma. 
 




Fig. 3-12. Position of TRAF3 mutations in relation to protein domains. An 
overview of the variants identified, showing the amino acid position and 
predicted protein domain of each variant.  
 
TRAF: tumour necrosis factor activating factor; RING: really interesting new 
gene; MATH: meprin and TRAF homology.  
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Table 3-9. TRAF3 synonymous variants identified in the present study. 






























C-T Synonymous 1 Heterozygous 
1 










































This thesis investigated new immunohistochemical and genetic markers which 
could be useful in subclassifying canine lymphomas.  
 
C-kit, CD30, and clusterin were all able to be used in canine lymphoma, and 
nearly 40% (18/46) of TCLs assessed in this study were positive for at least one 
of the immunohistochemical markers investigated. RNA-seq and Sanger 
sequencing were both able to detect mutations in the TRAF3 gene, and 36% of 
BCLs had a deleterious TRAF3 mutation detected. 
 
4.1 Assessment of novel immunohistochemical markers to 
improve canine T-cell lymphoma subclassfication 
Currently, due to a lack of validated diagnostic methods, the majority of canine 
high-grade TCL are classified as PTCL-NOS. As more diagnostic techniques 
become available, it is almost certain that this classification will be further 
refined, being subdivided into different groups with significant differences in 
prognosis and treatment. This study aimed to assess several IHC markers that 
are routinely used for human lymphoma subclassification in a population of 
canine lymphoma samples. The population we assessed was predominantly TCL, 
as there is currently a significant lack in the ability of veterinary oncologists to 
subclassify these cases. The markers initially selected included markers of ALCL 
(CD30, ALK), and Tfh (PD-1, CXCR5). After difficulties were encountered 
optimising these antibodies for canine samples, clusterin and c-Kit were also 
added. Clusterin has a possible role as a marker of ALCL in human lymphoma. 
C-Kit has no defined role in human lymphoma diagnosis, however it has not 
been assessed in canine lymphoma. We aimed to characterise c-Kit staining in 
a variety of canine lymphomas and determine whether this marker might have 




This study identified several B-cell and T-cell lymphoma cases with positivity 
for the IHC markers tested (c-Kit, CD30, clusterin). Most cases (17/18 TCL and 
3/3 BCL) were positive for only one of the assessed markers. One case (case 28 
– high-grade subcutaneous TCL) was positive for both CD30 and clusterin, 
however the pattern of staining was different for the different stains, indicating 
that the populations of positive cells were not identical in both samples 
(although there might have been overlap). 
 
C-Kit IHC has been extensively reported in canine mast cell tumours with either 
membranous or cytoplasmic staining, however it has been infrequently reported 
in canine lymphoma. The largest study assessed 25 cases of canine lymphoma 
(14 BCL, 15 TCL) using ICC, and found 6/14 BCL and 7/11TCL were positive 
respectively, with all cases showing cytoplasmic staining of varying intensity 
(Giantin et al., 2013). This study provided no information on the 
subclassification of the lymphomas beyond BCL or TCL. A second study 
investigating the use of masitinib in the treatment of epitheliotropic T-cell 
lymphoma found no expression of c-Kit when 8 tumours were assessed using 
immunohistochemistry (Holtermann et al., 2016). A case report of a dog with 
epitheliotropic lymphoma identified moderate cytoplasmic staining (Shiomitsu 
et al., 2012). A golgi staining pattern for c-Kit in canine samples has not 
previously been described, however it has been reported in some human 
tumours (Hughes et al., 2004, Jaramillo et al., 2012a). The significance of the 
golgi staining pattern is unknown, however in gastrointestinal stromal tumours 
golgi c-Kit staining pattern has been associated with c-Kit mutations (Jaramillo 




C-Kit IHC studies in human lymphoma have provided contradictory and 
inconsistent results. Regarding CD30 positive lymphoma subtypes, different 
studies have found either frequent (Pinto et al., 1994) or very infrequent 
(Rassidakis et al., 2003, Rassidakis et al., 2004) c-Kit positivity, with no known 
reason for this discrepancy. Similarly, a study of human DLBCL found 37% of 
cases showed some c-Kit positivity (Vakiani et al., 2005), however a second 
study of c-Kit expression in 1166 cases of lymphoma, which included 385 cases 
of DLBCL, found only two cases positive for c-Kit, neither of which was DLBCL. 
These inconsistencies have meant that c-Kit IHC has not found a role in the 
diagnosis or management of human lymphoma.  
 
In our study we found that all c-Kit positive cases were high grade TCL. 2/5 of 
the positive cases were high grade gastrointestinal lymphoma, which 
represented 20% (2/5) of all high grade gastrointestinal lymphoma cases 
assessed in the study. Also 2/5 positive cases were cutaneous lymphoma (one 
non-epitheliotropic, one epitheliotropic). These results could indicate that TCL, 
particularly high grade gastrointestinal and possibly cutaneous TCL, is more 
likely to be c-Kit positive. However, frequent c-Kit positivity in cases of 
cutaneous lymphoma is not supported by the previously mentioned study 
assessing c-Kit IHC in 8 dogs with epitheliotropic lymphoma, which found no 
positive cases. It would have been interesting to assess our samples for c-Kit 
mutations to determine whether IHC positivity, or staining pattern, correlated 
with mutation status. It would also be interesting to assess if c-Kit positive cases 
have a different prognosis or respond better to c-Kit inhibitors (such as 
toceranib and masitinib), compared to c-Kit negative cases. Unfortunately this 




CD30 IHC is essential for the subclassification of human lymphoma, as CD30 
positivity is obligatory in the diagnosis of ALCL. CD30 may also be prognostic in 
some lymphoma subtypes such as DLBCL (Hao et al., 2015, Hu et al., 2013). 
Currently there is no defined use for CD30 in canine lymphoma, however it has 
been used in a previous case report (Pittaway et al., 2018) and case series 
(Stranahan et al., 2019) to diagnose cases of ALCL. In our study, three cases 
were positive for CD30, all of which were TCL. Only one case showed diffuse 
staining, with the other two cases having <1% of neoplastic cells positive. In 
humans ALCL makes up ~16% of all TCL (Swerdlow et al., 2008). The prevalence 
of ALCL in the canine TCL population is unknown, partly due to the lack of 
validated diagnostics (eg CD30 IHC) required to definitively differentiate ALCL 
from other TCL subtypes. Seven percent (3/46) of TCL cases were positive in 
our study. It is unknown whether these cases were truly ALCL. Human ALCL 
classically show atypical lymphoid cells with pleomorphic nuclei and 
membranous-golgi CD30 positivity in the majority of neoplastic cells (Swerdlow 
et al., 2008). Previous reported canine cases of ALCL have shown membranous 
to cytoplasmic CD30 positivity in the majority (50-100%) of neoplastic cells. In 
our study, 2/3 positive cases showed only infrequent (<1%) staining of 
neoplastic cells, and in one of these cases the neoplastic population comprised 
small-intermediate lymphocytes, therefore it would appear to be unlikely that 
these two cases truly represented ALCL.  
 
ALCL in humans can be further subclassified into four subtypes: ALK negative 
primary systemic ALCL, ALK positive primary systemic ALCL, primary cutaneous 
ALCL, and breast implant associated ALCL. The third positive case reported in 
our study, which was intermediate-large cell non-epitheliotropic cutaneous TCL 
and showed diffuse moderate CD30 positivity, could have been a true case of 
primary cutaneous ALCL. Future studies assessing CD30 positivity, particularly 
to diagnose ALCL cases, are needed to further assess if this subclassification 
has prognostic significance in canine lymphoma. Furthermore, it would be 
interesting to trial treatment with CD30 immunotherapy (bentuximab vedotin) 
in these cases to determine whether this is a viable treatment option for canine 





Clusterin IHC does not have a defined role in the management of human 
lymphoma. The majority of ALCL cases are positive for clusterin, leading to the 
suggestion that clusterin could be used as a possible marker of ALCL in cases of 
poorly differentiated round cell tumours (Nascimento et al., 2004). In our study, 
only one of the possible ALCL CD30 positive cases (case 28) was also positive 
for clusterin; however, as previously mentioned, this case is unlikely to be a 
true example of ALCL. In our study the prevalence of positivity was similar 
between TCL and BCL, with 11/43 (26%) TCL and 3/13 (23%) BCL cases positive. 
All cases showed golgi staining which is consistent with clusterin IHC reports in 
human lymphoma (Nascimento et al., 2004, Olsen et al., 2009), however the 
intensity and percentage of positive staining cells varied between cases. In 
human lymphoma, there have been conflicting results regarding the proportion 
of neoplastic cells that stain positively for clusterin. Nascimento et al 
(Nascimento et al., 2004) found that 22/33 of clusterin-positive ALCL cases had 
>25% neoplastic cells positive for clusterin, and 15/22 of the positive cases had 
>75% of neoplastic cells positive. However a separate study by Olsen et al (Olsen 
et al., 2009) found that the majority (63/71) of clusterin-positive 
lymphoproliferative diseases showed <25% of neoplastic cells being positive, 
and 42/63 positive cases showed <1% of neoplastic cells being positive. The 
results of our study are more in line with Olsen et al, with all positive cases 
showing less than 25% of neoplastic cells positive for clusterin. As with the other 
markers assessed in our study, it would be interesting to assess clusterin in a 
larger prospective study to determine whether clusterin positivity is of 
prognostic significance. 
 
Several other T-cell markers had to be abandoned in this study due to an 
inability to confirm specific positive staining on canine tissue within the 
timeframe of the project. These included the Tfh-cell markers CXCR5 and PD1, 
and the ALCL marker ALK. CXCR5 and ALK IHC have never been reported in 




ALK has previously been assessed in canine pulmonary adenocarcinomas 
(Mariotti et al., 2014). In this study increased ALK expression was found with 
RT-PCR, however ALK IHC was negative. As in our study, it was not clear 
whether the ALK IHC was negative due to lack of the ALK antigen, lack of IHC 
optimisation for canine tissue, or insufficient homology between the canine and 
human ALK epitopes to allow anti-human ALK antibodies to bind. A second study 
(Hocker et al., 2017) assessed in situ phosphorylation of ALK in 16 canine nasal 
carcinomas. This study found 43.7% of cases had a phosphorylated ALK, but did 
not assess ALK with IHC.  
 
A major hurdle in using ALK in canine IHC is the lack of a reliable positive canine 
control tissue to confirm specific positive results in the dog. Aside from the two 
studies mentioned above, no other studies have assessed canine ALK and only 
one of the above studies attempted ALK IHC, which was unsuccessful. In our 
study we did not have access to reliable positive human control samples, such 
as embryonic brain, ALK positive ALCL, or appendix/small intestine. In the 
human tonsil and Hodgkin’s lymphoma samples assessed, no positive staining 
cells were noted, as expected. In the canine tonsil sample, no positive staining 
cells were identified, which could have been due to lack of antigen (which is 
likely based on the localisation of human ALK antigen), insufficient homology 
between the canine and human ALK epitope, or due to suboptimal IHC protocol 





CXCR5 and PD-1 IHC were also unsuccessful in our study. Similar to ALK it is not 
clear whether this was due to lack of antigen in our samples, lack of homology 
between the human antigen and the canine epitope, or due to the IHC protocol 
used. CXCR5 and PD-1 are markers of Tfh. In a study assessing 146 human PTCLs 
(Rodríguez-Pinilla et al., 2008), 29% were found to have arisen from Tfh on the 
basis of PD-1 positivity. A previous study successfully used PD-1 IHC in canine 
samples (Choi et al., 2020). Unfortunately, the antibody used in this study is 
not commercially available so was not available for our study. The PD-1 and 
CXCR5 antibodies used in our study have not previously been used in canine 
IHC. Tonsils are an appropriate control for CXCR5 and PD-1 in human IHC. Tonsil 
tissue should contain CXCR5 positive lymphocytes in the germinal centres and 
mantle zones, and PD-1 positive macrophages in the germinal centres and 
epithelial crypt cells (Smith et al., 2003). Unfortunately our canine tonsil 
controls were uniformly negative with all attempted IHC protocols. It is not 
clear why we were unable to identify positive cells in our IHC and we were 
unfortunately not able to optimise the CXCR5 of PD-1 stains within the 
timeframe of the project. 
 
Future work to optimise these stains for canine lymphoma samples is warranted 
in order to identify canine TCLs of Tfh origin, as this subclassification suggests 





Our study had several limitations. First and foremost, we were not able to, with 
the help of an experienced veterinary haematopathologist, systematically 
review the original histopathology and immunophenotyping to assign each case, 
to the extent currently possible within veterinary medicine, a WHO lymphoma 
subtype. We designated cases as high grade or low grade and assigned their 
anatomic location based on review of the animal history (where available) and 
histology/immunophenotyping reports. The next major limitation was our 
inability to optimise several of our intended IHC markers for canine tissue, 
resulting in us having to abandon our investigation into these markers (CXCR5, 
ALK, PD-1). The optimisations were performed in a commercial laboratory by 
an experienced technician; however, due to time constraints, there was 
difficulty co-ordinating the staining and review of the slides by the author and 
a pathologist. Had time and resources allowed, the author ideally would have 
performed the optimisation and assessed all attempts with the guidance of a 
pathologist. Another difficulty, particularly with the ALK antibody, was the lack 
of a suitable canine control tissue. No validated/confirmed ALK positive canine 
tissue has been identified. Confirmed canine ALCL (CD30 positive) cases might 
have been promising candidates for ALK positive control tissues. In humans, ALK 
positive ALCL is more common that ALK negative lymphoma (ALK positive cases 
comprise ~70% of all ALCL cases). If this is similar in canine ALCL then it is likely 
that ALK positive cases would be found in a group of confirmed ALCL cases (for 
example in the group of 13 ALCL cases described by Stranahan et al (Stranahan 
et al., 2019)). This difficulty highlights the need for more validated IHC markers 
in canine lymphoma, as if we were able to easily identify CD30 positive cases, 
we would be better able to identify the population of cases for which ALK IHC 




Overall the proportion of TCL cases staining positive for the markers 
investigated was low, with only 11%, 7%, and 26% of cases considered positive 
for C-kit, CD30 and clusterin respectively. This low proportion of positive cases 
results in low absolute numbers of positive cases to assess for trends in the 
characteristics of positive cases. Assessing a larger group of TCL cases would be 
interesting to see if the results obtained in this study are repeatable in a larger 
population, and to identify more positive cases that can be further assessed to 
determine the significance of positivity with these markers. The low proportion 
of positive cases could also limit the clinical usefulness of these markers and 
the benefit of the markers in providing prognostic or therapeutic information 
will need to be established to justify the cost and sampling requirements to the 
owner and patient.  
 
Our study has confirmed that canine lymphoma has variable c-Kit, CD30 and 
clusterin IHC characteristics, and has detailed the staining characteristics in a 
variety of canine lymphoma samples. Future work is needed to assess whether 
these characteristics can be used to subclassify canine lymphoma into 
prognostically different groups, or if they can be used to direct therapy. Ideally 
future studies would prospectively enrol dogs with TCL, and apply these 
markers at initial diagnosis, then follow the cases to test whether these markers 
correlate with outcome, or correlate with specific morphological subtypes. 
Additionally it is likely that human anti-neoplastic therapies will become 
available for use in dogs in future, since these markers could be useful in 
predicting response to these medications (for example using anti-CD30 
brentuximab vedotin in CD30 positive cases).  
 
Currently there are few methods of subclassifying canine TCL beyond basic 
morphology and T-cell immunophenotype. This results in a group termed PTCL-
NOS which, when investigated, show variable treatment responses and survival 
times. This is most likely due to this group containing several distinct TCL 
diseases which we are currently unable to distinguish. The three stains assessed 
in this study exclusively (c-Kit, CD30) or predominantly (clusterin) stained TCL 




4.2 Investigation of TRAF3 mutations in dogs with B-cell 
lymphoma 
Our study aimed to assess a cohort of dogs with BCL to confirm and add to the 
findings of previous studies. The results of our study support previous findings 
that TRAF3 mutations are frequent in cases of cBCL. In our study TRAF3 
mutations were present in 36% of cBCL patients. This is similar to previous 
studies, which found mutations in 30-44% of cBCL cases (Bushell et al., 2015, 
Elvers et al., 2015). We also assessed a cohort of dogs with non-BCL diseases 
(including four dogs with TCL) to determine whether TRAF3 mutations are 
specific for BCL, or if they occur with other diseases. Deleterious mutations of 
TRAF3 were only identified in patients with cBCL, which suggests that this gene 
is important in the pathogenesis of cBCL.  
 
The cBCL and cTCL cases included in this study were not further subtyped (apart 
from one case with a confirmed diagnosis of TZL), and therefore it is likely that 
different cBCL and cTCL subtypes were included. Similar to human BCL, cBCL 
comprises a diverse group of distinct diseases. The most common BCL subtype 
in humans and dogs is DLBCL (Valli et al., 2011), and it is likely that the majority 
of cBCL included in this study were DLBCL. Histology and IHC on all cases would 
be required to confirm this. As cBCL comprise a heterogeneous group of 
diseases, it is likely that different subtypes have different mutational 
characteristics, and future studies to assess how TRAF3 mutations relate to 




TRAF3 is a member of the tumour necrosis factor receptor-associated factor 
(TRAF) family of cytoplasmic adaptor proteins (Moore et al., 2015) and part of 
the CD40 signalling cascade which regulates proliferation, immunoglobulin class 
switching and apoptosis (Elvers et al., 2015). It is considered a tumour 
suppressor gene, and loss of TRAF3 function has been implicated in human 
tumours including several types of lymphoma, and multiple myeloma as well as 
other malignancies (Bushell et al., 2015). Pro-survival signalling (including B-
cell activating factor stimulation) results in trimerization of TRAF3 with other 
proteins, inhibiting its function and ultimately inducing the transcription of 
anti-apoptotic Bcl2 family proteins, leading to B-cell survival (Moore et al., 
2015). TRAF3 also negatively regulates NFkB by targeting NFkB-inducing kinase 
for ubiquitination and degradation (Bushell et al., 2015, Sun, 2011). Therefore, 
reduced TRAF3 activity leads to an upregulation of NFkB activity.  
 
The TRAF3 protein has several domains with specific functions (see Fig. 3-12). 
The coiled coil domains are responsible for hetero-oligomerisation among TRAF 
family members, which is crucial for interactions between the TRAF proteins 
and their substrates (Hacker et al., 2011, Qian Yin, 2009). The meprin and TRAF 
homology (MATH) domain is necessary for receptor interaction and interactions 
with adaptor proteins (Qian Yin, 2009, Hacker et al., 2011). All mutations 
identified in the current study would have resulted in premature truncation or 
change of the TRAF3 protein before or within these domains, and therefore 




In general, most mutations in neoplasms are suspected to be somatic, 
developing within the tumour as part of tumour initiation and progression. In 
the present study the majority of detected mutations were suspected to be 
somatic. In the five dogs with TRAF3 mutations and matched tissue, only one 
had the mutation identified in the matched tissue, suggesting a germline 
variant. However, the matched DNA samples were collected from peripheral 
blood, so detection of the mutation in circulating neoplastic cells, or free 
tumour DNA in the blood, cannot be completely excluded. While it is possible 
that this variant is a germline polymorphism, we did not find this variant in dogs 
without cBCL, as was seen with the synonymous variants. This suggests that the 
change may be a genuine germline mutation. A previous study found 17.5% of 
cBCL TRAF3 mutations were germline (Bushell et al., 2015), which is similar to 
the current study (1/5 dogs with matched tissue). Germline mutations in TRAF3 
could result in a genetic predisposition to developing cBCL. Genome wide 
association studies (GWAS) are needed to confirm this. 
 
The prevalence of TRAF3 mutations in our study was similar to previous studies 
(36% vs 30-44%). This is despite sequencing only exons 9, 10 and 11 of the TRAF3 
gene. This decision was made on the basis of RNA-Seq results (Waugh, 2015) 
which only identified variants in these exons. These three exons constitute 51% 
of the entire TRAF3 sequence and a previous study of TRAF3 mutations in cBCL 
(Bushell et al., 2015) found that the majority of mutations occurred within 
exons 9, 10 and 11; however, some mutations were identified in the other 
exons. As we did not sequence the entire gene, it is possible that our results 
might have underestimated the true prevalence of mutations in our population.  
 
Most of the identified mutations (9/11) were heterozygous, meaning these 
patients also had a wild-type allele detected. However, TRAF3 can have a 
dominant-negative effect, allowing heterozygous mutations to result in 
phenotypic changes. Mutations to RING-type domain or zinc finger domain (not 
assessed in this study) can competitively displace normal TRAF3 if the C-
terminal TRAF3 domains on the mutated protein are normal, and mutations to 
the C-terminal TRAF3 domains (identified in this study) can prevent normal 




This study has several limitations. Similar to many veterinary studies, the 
sample size was small. Given the prevalence of the mutations, this leads to 
identification of only a small overall number of mutations. Bulk Sanger 
sequencing was used, which is insensitive to mutations occurring at ~<20% allele 
frequency (MacConaill, 2013), so mutations might have been missed if they 
occurred in only a small proportion of the tumour cells, or if there was a 
significant number of non-tumour cells within the samples tested. This means 
the true prevalence of TRAF3 mutations could have been underestimated. Also, 
the majority of samples did not have matched non-tumour tissue to assess 
whether the variants were germline or somatic. Despite the small numbers of 
matched samples, the proportion of germline and somatic mutations found in 
this study was similar to previous studies. Only a portion of the genes were 
sequenced in this study, which may have led to some mutations being missed, 
and an underestimation of the total number of mutations. Sequenced exons 
were selected on the basis of RNA-Seq data (Waugh, 2015) and previous studies 
(Elvers et al., 2015, Bushell et al., 2015) and while these methodologies 
generally showed good correlation, in 4/12 instances discrepancies were 
identified (two variants identified only on RNA-Seq and two identified only on 
Sanger sequencing), possibly as a result of sequencing error in the RNA-Seq 
dataset. Ideally, sequencing of the full genes would have been performed. 
Despite this, it is likely that we were able to identify the majority of mutations 
present.  
 
This study adds further support to the suggestion that TRAF3 mutations are 
important in the pathogenesis of cBCL. Future studies looking at potential 
prognostic and therapeutic implications of these mutations are needed. 
Unfortunately, due to the heterogeneity in treatment modalities and clinical 
information available for the included cases in this study, correlation between 
TRAF3 status and BCL morphological subtype or prognosis was not possible. 
Studies assessing TRAF3 germline mutations and predisposition to neoplasia 





Precise subclassification of lymphoma is crucial to accurately prognosticate and 
optimise therapies. IHC and molecular techniques are routinely used to 
subclassify human lymphoma. Canine lymphoma subclassification remains far 
behind human lymphoma, partly due to the difficulty in performing large scale 
studies to validate new diagnostic techniques.  This study has detailed the IHC 
characteristics of a variety of canine lymphoma samples using novel IHC stains, 
some of which have defined roles in human lymphoma TCL subclassification, 
and has confirmed the high prevalence of TRAF3 mutations in canine BCL and 
described their characteristics. This study also indicates that TRAF3 mutations 
are specific for BCL, as they were not identified in any other diseases.  These 
preliminary investigations, however, will hopefully provide a basis for future 
studies to assess these characteristics for their prognostic and therapeutic 
significance. If significance is found, then these factors might be adopted in 
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